Inhibitory compounds

Abstract

The present invention relates at least in part to certain compounds that function as inhibitors of MutSβ. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which MutSβ activity is implicated, such as, for example, repeat expansion diseases or disorders, as well as to increase the efficiency of genome editing.

Description

INHIBITORY COMPOUNDSFIELD OF THE INVENTION

[0001] The present invention relates to certain compounds that function as inhibitors of MutSβ. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which MutSβ activity is implicated, such as, for example, diseases related to somatic expansion of expanded simple nucleotide repeats.BACKGROUND OF THE INVENTION

[0002] Mismatch repair (MMR) is a highly conserved DNA repair pathway that promotes genome stability in all organisms which recognises and repairs erroneous insertion, deletion or mis-incorporation of nucleotides that can arise during DNA replication, repair or recombination. MMR is thus one of the key pathways that participates in the cellular response to certain types of DNA damage. In addition to DNA damage response roles, MMR is employed during meiosis in eukaryotes and immunoglobulin maturation / diversification in mammals.

[0003] MMR predominantly corrects DNA base mismatches and insertion / deletion (indel) loops that can occasionally arise during normal DNA replication processes. Base pair mismatches occur when incorrect nucleotides (for example, in response to oxidative damage) are inserted into the newly synthesised DNA strand and escape the proofreading function of DNA polymerases. Indel loops commonly arise in the context of microsatellites which are highly polymorphic, short tandem repeat DNA sequences distributed throughout genomes. Typically, at microsatellites, especially in the context of longer repeats, the template and primer strands are prone to slippage (dissociation and reannealing) during replication; this can lead to the formation of loop structures and ultimately result in a discordant number of repeat units between the template and newly synthesised strand.

[0004] Mammalian MMR can be separated into four steps: (1) mismatch recognition mediated by MutS heterodimers; (2) recruitment of MutL heterodimers which connect the mismatch recognition signal to where the DNA strand scission begins in a strand-specific fashion; (3) excision of the errant, error-containing DNA strand and (4) re-synthesis of the excision gap using the remaining DNA strand as a template.

[0005] In humans, mismatch recognition by MutSa (comprised of MSH2 and MSH6 gene products) or MutSβ (comprised of MSH2 and MSH3 gene products) heterodimers initiate the MMR pathway. These obligate heterodimers differ in their substrate preferences but there are considerable overlaps between the substrates recognised and processed. MutSa recognizes base-base mismatches and some insertion-deletion mismatches with a preference for shorterindels (1-3 nucleotides), whereas MutSβ predominantly processes larger indels of 3+ nucleotides. MutSa also contributes to the recognition of certain types of DNA damage such as oxidised nucleotides and can participate in the checkpoint response to such lesions. Similarly, MutSβ may cooperate with the nucleotide excision repair machinery in the repair of interstrand cross-links. Furthermore, both heterodimers have been implicated in the production of certain genetic variants. MutSa participates in the somatic hypermutation phase of immunoglobulin gene affinity maturation, and MutSβ is required for the triplet repeat expansions that are responsible for a number of neurodegenerative diseases. Additionally, when MMR pathway signalling is abolished (termed deficient MMR or dMMR), this typically results in increased instability at these repetitive regions at multiple genome loci, a process termed microsatellite instability (MSI).

[0006] Binding of MutSa or MutSβ heterodimers to the mismatch results in the ATP-dependent recruitment of a MutL heterodimer (either MutLα comprising MLH1 and PMS2 gene products, MutLβ comprising MLH1 and PMS1 or MutLγ comprising MLH1 or MLH3 gene products) to form a ternary complex. This ternary complex forms interactions with additional proteins including proliferating cell nuclear antigen (PCNA) and exonuclease 1 (EXO1) which enable successful completion of MMR sequelae.

[0007] Short tandem repeats (STR) represent one of the most abundant class of variations in human genomes, are polymorphic by nature and become highly unstable in a length dependent fashion. The expansion of repeat length above a threshold is a well-established feature of more than 50 hereditary human disorders mainly affecting the nervous system, with many likely remaining to be identified due to improvements in detection by sequencing-based methods. Coding repeat expansion diseases include but are not limited to brachydactyly and cleidocranial dysplasia (BCCD); blepharophimosis, ptosis and epicanthus inversus (BPES); cleidocranial dysplasia (CCD); congenital central hypoventilation syndrome (CCHS); dentatorubropallidoluysian atrophy (DRPLA); early infantile epileptic encephalopathy type 1 (EIEE1); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); hand-foot-genital syndrome (HFGS); holoprosencephaly type 5 (HPE5); mental retardation with isolated growth hormone deficiency (MRGH); oculopharyngeal muscular dystrophy (OPMD); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 17 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA17); synpolydactyly (SPD); X-linked mental retardation and abnormal genitalia (XLAG); X-linked mental retardation with or without growth hormone deficiency (XLMR, XLMRGHD). Non-coding repeat expansion diseases include but are not limited to benign adult familial myoclonic epilepsy (BAFME); Baratela-Scott syndrome (BSS); cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS); myotonic dystrophy type 1 (DM1); myotonic dystrophy type 2 (DM2); progressive myoclonus epilepsy type 1 or Unverricht-Lundborg diseae (EPM1); familial adult myoclonic epilepsy (FAME); FGF14-linkedParkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA); frontotemporal dementia / amyotrophic lateral sclerosis (FTD / ALS); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); global development delay, progressive ataxia and elevated glutamine (GDPAG); neuronal intranuclear inclusion disease (NIID); oculopharyngodistal myopathy type 1 (OPDM1); oculopharyngodistal myopathy type 2 (OPDM2); oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1), spinocerebellar ataxias types 8, 10, 12, 27B, 31, 36, 37 (SCA8, SCA10, SCA12, SCA27B, SCA31, SCA36, SCA37); X-linked dystonia parkinsonism (XDP).

[0008] Repeat expansion diseases can be dominant (e.g. Huntington’s disease) or recessive (e.g. Friedreich’s ataxia) and have the common feature of inheritance of an expansion of a normally polymorphic repeat in the disease-associated gene above a defined threshold. The number of repeats required to pass this threshold varies for each disease, although exonic repeats generally have lower thresholds than intronic repeats. Coding or exonic repeat diseases generally lead to a toxic gain of function of the resulting protein gene product, whereas non-coding intronic repeats generally lead to reduced expression of the protein gene product. In both cases this leads to dysfunction and death in vulnerable cell types, eventually resulting in clinical signs and symptoms. In addition to inheritance of an expanded allele there is now strong evidence that these repeat expansions are unstable and expand further during the lifespan of the individual. This expansion happens at the individual cell level (i.e. somatic expansion) and the extent of expansion in a given cell type / tissue typically correlates tightly with how vulnerable it is to degeneration during the course of the disease. The faster the expansion in mutation carriers, the greater the impact on disease measures such as age-of-onset, progression and severity.

[0009] The term “somatic instability” describes the fact that a repetitive sequence (e.g. a trinucleotide repeat tract such as CAG for huntingtin) is unstable at an individual cell level (i.e. somatic) which leads to a shift in the CAG repeat profiles at the population level. Somatic instability can lead to expansion or contraction of the repeat sequence but is usually expansion-biased in the context of a disease-causing repeat expansion. Huntington’s disease is triggered by the inheritance of an expanded CAG repeat sequence in the HTT gene longer than 40 consecutive CAG repeats (though it should be noted that 36-39 consecutive CAG repeats align with incomplete penetrance): these repeats have increased propensity to expand further. The rate of somatic CAG repeat expansion is influenced by the number of consecutive repeats, time and cell-type. The pathogenic repeat threshold in expansion-prone cell types such as striatal projection neurons (also known as medium spiny neurons) is longer than 40 CAG and is currently unknown. However, post-mortem brain tissue data indicate that greater than 150 CAG repeats (via somatic expansion over time) is associated with measurablepathophysiology (profoundly altered gene expression profiles) in the cells bearing these highly expanded repeats. It is now widely accepted that the somatic expansion of a CAG repeat sequence in HTT in brain cells is the first step in the molecular pathogenesis of Huntington’s disease, followed by a second process that leads to cell dysfunction once a CAG repeat threshold has been achieved. The rate of somatic CAG repeat expansion is thus the key driver for the age of onset and rate of progression of the disease. Slowing or stopping somatic instability could significantly mitigate disease progression and provide a much sought after disease-modifying therapy.

[0010] For at least a subset of these repeat expansion diseases, MMR proteins are modifiers of repeat expansions and clinical profile. Strong genetic and mechanistic data indicate that MutSβ (gene products of MSH2 and MSH3) drives somatic expansion of these repeats. Reduction in MutSβ expression or function, for example by point mutations to ablate its ATPase function, block somatic expansion. Thus, methods of arresting, or reversing, somatic repeat expansions is hypothesised to be an effective therapeutic approach to slow or stop repeat disease progression.

[0011] While MMR is essential for maintaining the integrity of the genome, it can also act as a barrier to efficient genome editing.

[0012] More recently, multiple labs have shown that reduction or inhibition of MMR significantly enhanced the efficiency of prime editing (PE) while abating the frequency of unintended indels. PE was established in the Liu lab and utilises three components: (i) Cas9 nickase to nick the non-target strand; (ii) prime editing single guide RNA (pegRNA) to bind the target strand and (iii) a reverse transcriptase to reverse transcribe from the 3’ end of the nontarget strand according to the information provided by the pegRNA. PE is a precise and versatile genome editing technique that enables all types of base conversions and small fragment deletion or insertion in the genome. One challenge with PE is it has a much lower efficiency than other types of Cas9-derived editing approaches because endogenous MMR processes often revert the sequence back to the original sequence. Accordingly, increasing the efficiency of PE, together with reducing indels, through the use of MutSa and / or MutSβ inhibitor treatment ex vivo and / or in vivo may enhance the potential for clinical translation and therapeutic use of prime editors.

[0013] Other genome editing techniques aiming to introduce specific changes in the DNA sequence by providing a template that serves as a repair template could benefit from inhibiting MMR. As MMR can recognize and repair mismatches between the template and the target DNA, leading to the removal or correction of the desired edits, MutSa and / or MutSβ inhibitors could prevent the rejection of the edit and increase editing efficiency. The use of a template is a crucial aspect of certain gene editing techniques, such as homology-directed repair (HDR). HDR relies on the introduction of an exogenous DNA template that serves as a repair templateto guide the desired genetic modifications.

[0014] Some HDR-based gene editing methods that commonly utilize a template include CRISPR-Cas9, ZFN (Zinc Finger Nucleases) and TALENs (Transcription Activator-Like Effector Nucleases). In these approaches, nucleases introduce double-strand breaks (DSBs) at specific target sites in the genome. These DSBs can then be repaired using an exogenous DNA template as a guide for HDR, enabling precise insertion, deletion, or replacement of genetic material. Nuclease-free editing methods utilising ssODN (single-stranded oligonucledotides) as a template for desired edit were also shown to benefit from lowering activity of MMR factors and has been used to create mouse strains.

[0015] Therefore, there is an on-going need for compounds that function as inhibitors of MutSβ.

[0016] The present invention was devised with the foregoing in mind.SUMMARY OF THE INVENTION

[0017] According to a first aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0018] According to a further aspect of the present invention, there is provided a pharmaceutical composition comprising a compound as defined herein, ora pharmaceutically acceptable salt, hydrate or solvate thereof, in admixture with a pharmaceutically acceptable diluent or carrier.

[0019] According to a further aspect of the present invention, there is provided a method of inhibiting MutSβ activity in vitro, ex vivo or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein. Suitably, the method comprises the selective inhibition of MutSβ activity in vitro, ex vivo or in vivo.

[0020] According to a further aspect of the present invention, there is provided a method of inhibiting somatic expansion of expanded simple nucleotide repeats in vitro, ex vivo or in vivo (e.g. in treating a repeat expansion disease or disorder), said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate orsolvatethereof as defined herein. Suitably, the somatic expansion is associated with MutSβ activity.

[0021] According to a further aspect of the present invention, there is provided a method of treating a disease or disorder in which MutSβ activity is implicated (e.g. a repeat expansion disease or disorder) in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0022] According to a further aspect of the present invention, there is provided a method of treating a repeat expansion disease or disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0023] According to a further aspect of the present invention, there is provided a method of treating a triplet repeat disease or disorder in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0024] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0025] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the inhibition of MutSβ activity, e.g. in cellular systems. The inhibition may be the selective inhibition of MutSβ activity.

[0026] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in inhibiting somatic expansion of expanded simple nucleotide repeats, e.g. in the treatment of a repeat expansion disease or disorder.

[0027] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the treatment of a disease or condition in which MutSβ activity is implicated (e.g. a repeat expansion disease or disorder).

[0028] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of a repeat expansion disease or disorder.

[0029] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of a triplet repeat disease or disorder.

[0030] According to a further aspect of the present invention, there is provided a use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament forthe inhibition of MutSβ activity, e.g. in cellular systems.

[0031] According to a further aspect of the present invention, there is provided a use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined hereinin the manufacture of a medicament for inhibiting somatic expansion of expanded simple nucleotide repeats, e.g. in treating a repeat expansion disease or disorder.

[0032] According to a further aspect of the present invention, there is provided a use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament forthe treatment of a disease or condition in which MutSβ activity is implicated (e.g. a repeat expansion disease or disorder).

[0033] According to a further aspect of the present invention, there is provide the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a repeat expansion disease or disorder.

[0034] According to a further aspect of the present invention, there is provide the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a triplet repeat disease or disorder.

[0035] Suitably, the repeat expansion disease or disorder may be selected from benign adult familial myoclonic epilepsy (BAFME); brachydactyly and cleidocranial dysplasia (BCCD); blepharophimosis, ptosis and epicanthus inversus (BPES); Baratela-Scott syndrome (BSS); cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS); congenital central hypoventilation syndrome (CCHS); dentatorubropallidoluysian atrophy (DRPLA); early infantile epileptic encephalopathy type 1 (EIEE1); familial adult myoclonic epilepsy (FAME); FGF14-linked Parkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA) frontotemporal dementia / amyotrophic lateral sclerosis (FTD / ALS); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); global development delay, progressive ataxia and elevated glutamine (GDPAG); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); hand-foot-genital syndrome (HFGS); holoprosencephaly type 5 (HPE5); mental retardation with isolated growth hormone deficiency (MRGH); myotonic dystrophy type 1 (DM1); myotonic dystrophy type 2 (DM2); progressive myoclonus epilepsy type 1 or Unverricht-Lundborg diseae (EPM1); neuronal intranuclear inclusion disease (NIID); oculopharyngodistal myopathy type 1 (OPDM1); oculopharyngodistal myopathy type 2 (OPDM2); oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 10, 12, 17, 27B, 31, 36, 37 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, SCA27B, SCA31, SCA36, SCA37); synpolydactyly (SPD); X-linked dystonia parkinsonism (XDP); X-linked mental retardation and abnormal genitalia (XLAG); or X-linked mental retardation with or without growth hormone deficiency (XLMR, XLMRGHD).

[0036] Suitably, the repeat expansion disease or disorder may be a triplet repeat disease ordisorder. The triplet repeat disease or disorder may be selected from dentatorubropallidoluysian atrophy (DRPLA); FGF14-linked Parkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); myotonic dystrophy type 1 (DM1); neuronal intranuclear inclusion disease (NIID;)spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 17, (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA17). More suitably, the triplet repeat disease or disorder is Huntington’s disease (HD).

[0037] According to a further aspect of the present invention, there is provided a method of increasing the efficiency of a gene editing technique, the method comprising conducting the gene editing technique in the presence of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0038] According to a further aspect of the present invention, there is provided a method of prime editing, the method comprising contacting a cell with: (1) a Cas9 nickase to nick a nontarget strand; (2) a prime editing single guide RNA (pegRNA) to bind the target strand; (3) a reverse transcriptase to reverse transcribe from the 3’ end of the non-target strand according to the information provided by the pegRNA; and (4) a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0039] In the method of prime editing described herein, the step of “contacting a cell” suitably comprises contacting a target gene or DNA in a cell.

[0040] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for gene editing in vitro, ex vivo or in vivo.

[0041] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in gene editing in vitro, ex vivo or in vivo.

[0042] Suitably, the gene editing technique referred to herein is any suitable gene editing technique in which host cell mis-match repair (MMR) factors are known to decrease the efficiency of the gene editing. Several available tools for gene editing use enzymes acting on DNA called nucleases and exploit intrinsic DNA repair pathways such as homology-directed repair (HDR), non-homologous end joining (NHEJ) which are both associated with double strand breaks (DSB)s. Specific examples of such DSB nucleases include ZFN (zinc finger nucleases), TALENs (Transcription activator like effector nucleases), CRISPR-Cas9 or CRISPR-Cas12 nucleases and Fanzor (an eukaryotic CRISPR-like RNA guided nucleases related to prokaryotic OMEGA system nucleases). Other forms of gene editing technology do not induce DSBs and use engineered or inactivated nucleases to either cut only a single strandof DNA. Specific examples of gene editing technologies that do not leverage DSBs include base editing (fusion of catalytically dead dCas9 enzymes to DNA deaminases which enable single nucleotide substitutions) and prime editing (fusion of a Cas9 nickase to a reverse transcriptase) and its related technology PASTE (programmable addition via site-specific targeting elements which leverages prime editing to insert AttB sites and then facilitate serine integrase proteins to insert larger sequences). Indeed, all editing methods using a singlestranded oligonucleotide (ssODN) as a template should benefit from MMR inhibition.

[0043] The gene editing technique may be a HDR-based gene editing method, e.g. CRISPR-Cas9, ZFN and TALENs.

[0044] According to a further aspect of the present invention, there is provided a process for preparing a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein.

[0045] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, obtainable by, or obtained by, or directly obtained by a process of preparing a compound as defined herein.

[0046] According to a further aspect of the present invention, there are provided novel intermediates as defined herein which are suitable for use in any one of the synthetic methods set out herein.

[0047] Features, including optional, suitable, and preferred features in relation to one aspect of the invention may also be features, including optional, suitable and preferred features in relation to any other aspect of the invention.BRIEF DESCRIPTION OF THE FIGURESFigure 1 shows details of the Lo-Q assay described in the examples section.Figure 2 shows a schematic of the procedure for the preparation of compound 14c.Figure 3 shows a schematic of the procedure for the preparation of compound 14e.DETAILED DESCRIPTION OF THE INVENTIONDefinitions

[0048] Unless otherwise stated, the following terms used in the specification and claims have the following meanings set out below.

[0049] It is to be appreciated that references to “treating” or “treatment” include prophylaxis as well as the alleviation of established symptoms of a condition. “Treating” or “treatment” of a state, disorder or condition therefore includes: (1) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a human that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (2) inhibiting thestate, disorder or condition, i.e., arresting, reducing or delaying the development ofthe disease or a relapse thereof (in case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or attenuating the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.

[0050] A “therapeutically effective amount” means the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to effect such treatment for the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, etc., ofthe mammal to be treated.

[0051] In this specification, “simple nucleotide repeats” (also known as microsatellites or short tandem repeat sequences) are known in the art and are short tandemly repeated DNA sequences comprising a repetitive unit of from 1-6 base pairs, where the motifs are repeated >5 times.

[0052] The term “prime editing” refers to programmable editing of a target DNA using a prime editor complexed with a pegRNA to incorporate an intended nucleotide edit into the target DNA through target-primed DNA synthesis. A target polynucleotide, e.g., a target gene of prime editing may comprise a double stranded DNA molecule having two complementary strands: a first strand that may be referred to as a “target strand” or a “non-edit strand,” and a second strand that may be referred to as a “non-target strand,” or an “edit strand”.

[0053] In this specification the term “alkyl” includes both straight and branched chain alkyl groups. References to individual alkyl groups such as “propyl” are specific for the straight chain version only and references to individual branched chain alkyl groups such as “isopropyl” are specific for the branched chain version only. For Example, “(1 -6C)alkyl” includes (1-4C)alkyl, (1 -3C)alkyl, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and f-butyl, as well as pentyl and hexyl isomers. A similar convention applies to other radicals, for example “phenyl(1-6C)alkyl” includes phenyl(1-4C)alkyl, benzyl, 1-phenylethyl and 2-phenylethyl etc.

[0054] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix, refers to any group having m to n carbon atoms.

[0055] An “alkylene,” “alkenylene,” or “alkynylene” group is an alkyl, alkenyl, or alkynyl group that is positioned between and serves to connect two other chemical groups. Thus, “(1-6C)alkylene” means a linear saturated divalent hydrocarbon radical of one to six carbon atoms or a branched saturated divalent hydrocarbon radical of three to six carbon atoms, for example, methylene, ethylene, propylene, 2-methylpropylene, pentylene, and the like.

[0056] “(2-6C)alkenylene” means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing at least one double bond, for example, as in ethenylene, 2,4-pentadienylene, and the like.

[0057] “(2-6C)alkynylene” means a linear divalent hydrocarbon radical of two to six carbon atoms or a branched divalent hydrocarbon radical of three to six carbon atoms, containing atleast one triple bond, for example, as in ethynylene, propynylene, and butynylene and the like.

[0058] “(3-8C)cycloalkyl” means a hydrocarbon ring containing from 3 to 8 carbon atoms, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or bicyclo[2.2.1]heptyl.

[0059] “(3-8C)cycloalkenyl” means a hydrocarbon ring containing at least one double bond, for example, cyclobutenyl, cyclopentenyl, cyclohexenyl or cycloheptenyl, such as 3-cyclohexen-1-yl, or cyclooctenyl.

[0060] “(3-8C)cycloalkyl-(1-6C)alkyl” means a (3-8C)cycloalkyl group covalently attached to a (1-6C)alkylene group, both of which are defined herein.

[0061] The term “halo” or “halogeno” refers to fluoro, chloro, bromo and iodo.

[0062] The term “heterocyclyl”, “heterocyclic” or “heterocycle” means a non-aromatic saturated or partially saturated monocyclic, fused, bridged, or spiro bicyclic heterocyclic ring system(s). Monocyclic heterocyclic rings contain from about 3 to 12 (suitably from 3 to 7) ring atoms, with from 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocycles contain from 7 to 17 member atoms, suitably 7 to 12 member atoms, in the ring, with from 1 to 8 (suitably 1, 2, 3, 4 or 5, more suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. Bicyclic heterocyclic(s) rings may be fused, spiro, or bridged ring systems. Examples of heterocyclic groups include cyclic ethers such as oxiranyl, oxetanyl, tetrahydrofuranyl, dioxanyl, and substituted cyclic ethers. Heterocycles containing nitrogen include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, and the like. Typical sulfur containing heterocycles include tetrahydrothienyl, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran, and hexahydrothiepine. Other heterocycles include dihydrooxathiolyl, tetrahydrooxazolyl, tetrahydro-oxadiazolyl, tetrahydrodioxazolyl, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothienyl and thiomorpholinyl such as tetrahydrothiene 1,1-dioxide and thiomorpholinyl 1,1-dioxide. A suitable value for a heterocyclyl group which bears 1 or 2 oxo (=O) or thioxo (=S) substituents is, for example, 2-oxopyrrolidinyl, 2-thioxopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioxoimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Particular heterocyclyl groups are saturated monocyclic 3 to 7 membered heterocyclyls containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, for example azetidinyl, tetra hydro furanyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetra hydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As the skilled person would appreciate, any heterocycle may be linked to another group via any suitable atom, such as viaa carbon or nitrogen atom. However, reference herein to piperidino or morpholino refers to a piperidin-1-yl or morpholin-4-yl ring that is linked via the ring nitrogen.

[0063] By “bridged ring systems” it is meant ring systems in which two rings share more than two atoms, see for example Advanced Organic Chemistry, by Jerry March, 4thEdition, Wiley Interscience, pages 131-133, 1992. Examples of bridged heterocyclyl ring systems include, aza-bicyclo[2.2.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, aza-bicyclo[2.2.2]octane, aza-bicyclo[3.2.1]octane and quinuclidine.

[0064] By “carbocycle” or a “carbocyclic ring”, we mean a saturated or partially saturated ring formed exclusively from carbon atoms. For example, the term “carbocyclic ring” encompasses cycloalkyl or cycloalkenyl ring systems.

[0065] By “spiro bicyclic ring systems” we mean that the two ring systems share one common spiro carbon atom, i.e. the heterocyclic ring is linked to a further carbocyclic or heterocyclic ring through a single common spiro carbon atom. Examples of spiro ring systems include 6-azaspiro[3.4]octane, 2-oxa-6-azaspiro[3.4]octane, 2-azaspiro[3.3]heptanes, 2-oxa- 6-azaspiro[3.3]heptanes, 7-oxa-2-azaspiro[3.5]nonane, 6-oxa-2-azaspiro[3.4]octane, 2-oxa- 7-azaspiro[3.5]nonane and 2-oxa-6-azaspiro[3.5]nonane.

[0066] “Heterocyclyl(1-6C)alkyl” means a heterocyclyl group covalently attached to a (1-6C)alkylene group, both of which are defined herein.

[0067] The term “heteroaryl” or “heteroaromatic” means an aromatic mono-, bi-, or polycyclic ring incorporating one or more (for example 1-4, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. The term heteroaryl includes both monovalent species and divalent species. Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five to twelve ring members, and more usually from five to ten ring members. The heteroaryl group can be, for example, a 5- or 6-membered monocyclic ring or a 9- or 10-membered bicyclic ring, for example a bicyclic structure formed from fused five and six membered rings or two fused six membered rings. Each ring may contain up to about four heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 3 heteroatoms, more usually up to 2, for example a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole nitrogen. In general, the number of basic nitrogen atoms present in the heteroaryl group, including any amino group substituents of the ring, will be less than five.

[0068] Examples of heteroaryl include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, isoindolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, benzothiazolyl, indazolyl, purinyl,benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalinyl, cinnolinyl, pteridinyl, naphthyridinyl, carbazolyl, phenazinyl, benzisoquinolinyl, pyridopyrazinyl, thieno[2,3b]-furanyl-, 2H-furo[3,2b]-pyranyl-, 5H-pyrido[2,3-d]-oxazinyl-, 1 H-pyrazolo[4,3-d]-oxazolyl, 4H-imidazo[4,5d]thiazolyl, pyrazino[2,3d]pyridazinyl, -imidazo[2,1 b]th iazolyl, -imidazo[1,2b][1,2,4]-triazinyl. “Heteroaryl” also covers partially aromatic bi- or polycyclic ring systems wherein at least one ring is an aromatic ring and one or more of the other ring(s) is a nonaromatic, saturated or partially saturated ring, provided at least one ring contains one or more heteroatoms selected from nitrogen, oxygen or -sulfur-. Examples of partially aromatic heteroaryl groups include for example, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 2-oxo-1,2,3,4-tetrahydroquinolinyl, dihydrobenzthienyl, dihydrobenzfuranyl, 2,3-dihydro-benzo[1,4]dioxinyl, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothienyl, 4,5,6,7-tetrahydrobenzofuranyl, indolinyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazinyl and 6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazinyl.

[0069] Examples of five membered heteroaryl groups include but are not limited to pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl groups.

[0070] Examples of six membered heteroaryl groups include but are not limited to pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl.

[0071] A bicyclic heteroaryl group may be, for example, a group selected from:a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyridine ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a pyrimidine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a pyrrole ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;a pyrazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;a pyrazine ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an imidazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an oxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; an isoxazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms;an isothiazole ring fused to a 5- or 6-membered ring containing 1 or 2 ring heteroatoms; a thiophene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms; a furan ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring heteroatoms;a cyclohexyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms; anda cyclopentyl ring fused to a 5- or 6-membered heteroaromatic ring containing 1, 2 or 3 ring heteroatoms.

[0072] Particular examples of bicyclic heteroaryl groups containing a six membered ring fused to a five membered ring include but are not limited to benzfuranyl, benzthiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolinyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl and pyrazolopyridinyl groups.

[0073] Particular examples of bicyclic heteroaryl groups containing two fused six membered rings include but are not limited to quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolizinyl, benzoxazinyl, benzodiazinyl, pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl and pteridinyl groups.

[0074] “Heteroaryl(1-6C)alkyl” means a heteroaryl group covalently attached to a (1-6C)alkylene group, both of which are defined herein. Examples of heteroaralkyl groups include pyridin-3-ylmethyl, 3-(benzofuran-2-yl)propyl, and the like.

[0075] The term “aryl” means a cyclic or polycyclic aromatic ring having from 5 to 12 carbon atoms. The term aryl includes both monovalent species and divalent species. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl and the like. In particular embodiment, an aryl is phenyl.

[0076] The term “aryl(1-6C)alkyl” means an aryl group covalently attached to a (1-6C)alkylene group, both of which are defined herein. Examples of aryl-(1-6C)alkyl groups include benzyl, phenylethyl, and the like.

[0077] This specification also makes use of several composite terms to describe groups comprising more than one functionality. Such terms will be understood by a person skilled in the art. For example heterocyclyl(m-nC)alkyl comprises (m-nC)alkyl substituted by heterocyclyl.

[0078] The term "optionally substituted" refers to either groups, structures, or molecules that are substituted and those that are not substituted. The term “wherein a / any CH, CH2, CH3group or heteroatom (i.e. NH) within a R1group is optionally substituted” suitably means that (any) one of the hydrogen radicals of the R1group is substituted by a relevant stipulated group.

[0079] Where optional substituents are chosen from “one or more” groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

[0080] The phrase “compound of the invention” means those compounds which are disclosed herein, both generically and specifically.Compounds of the invention

[0081] In a first aspect, the present invention relates to compounds, or pharmaceutically acceptable salts, hydrates or solvates thereof, having the structural formula (I) shown below:wherein:Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2, 3 or 4;each occurrence of RL1and RL2is independently selected from hydrogen or (1-2C)alkyl), or RL1and RL2taken together may form an oxo group;XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXB1)C(O)-, -N(RXB1)-, -N(RXBI)C(O)O-, -OC(O)N(RXBI)-, -N(RXBI)C(O)N(RXB2)-, -S(O)2N(RXBI)-, or - N(RXBI)SO2-, wherein RXBI and RXB2are each independently selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQiRQ2]n-, -[CRQiRQ2]n-(3-10C)cycloalkyl, -[CRaiRQ2]n-(3 to 10-membered heterocyclyl), - [CRQiRQ2]n-aryl and -[CRQiRQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQI and RQ2are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, NRQSRCM, C(O)RQS, C(O)ORQ3, OC(O)RQ3, C(O)N(RQ3)RQ4, N(RQ3)C(O)RQ4, S(O)yRm(where y is 0, 1 or 2), SO2N(RQ3)RQ4 or N(RQ3)SO2Rn; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl;R2is selected from hydrogen and (1 -3C)alkyl;R3is selected from hydrogen and (1 -3C)alkyl;bond a is either a single bond or a double bond, wherein:when bond a is a single bond:X is selected from -C(RXI)(RX2)-, -C(=O)-, -C(=NH)-, -C(=S)-; andY is selected from -C(RYI)(RY2)-, -C(=O)-, -C(=NH)-, -C(=S)-; orwhen bond a is a double bond:X is -C(RX1)- andY is -C(RYI)-;wherein:RX1and RX2are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy; Rxi and Rx2are linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring; orRY1and RY2are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy; orRYI and RY2are linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring, optionally substituted with halo, hydroxy, (1-3C)alkyl or (1- 3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1- 3C)alkoxy;R4is selected from hydrogen, halo, cyano, hydroxy, NR4aR4b, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, -[CH2]r-(3-12C)cycloalkyl, -[CH2]r(3- to 12-membered)heterocyclyl, -[CH2]raryl or -[CH2]r-heteroaryl wherein each of R4a and R4bis independently selected from hydrogen or (1 -3C)alkyl and integer r is 0, 1 or 2;wherein:any alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl in an R4group is optionally substituted by one or more RI6substituents independently selected from halo, hydroxy, cyano, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NR4aR4b, wherein R4aand R4b are each independently selected from H or (1- 2C)alkyl;Z is selected from -C(Rz2)(Rzs)-, -O-, or -NRzi, wherein:RZ1is selected from hydrogen or (1-2C)alkyl;Rzz and Rzs are each independently selected from hydrogen or (1 -3C)alkyl; or RZ2 and Rzs are linked such that, together with the carbon atom to which they are attached, they form a (3-5C)cycloalkyl or heterocyclyl ring;Rs is selected from phenyl, naphthyl or heteroaryl, wherein Rs is optionally substituted by one or more substituents R, wherein each RAis independently selected from: halo, hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, cycloalkyl, (3-6-membered)heterocyclyl and -[CH2]s-NR5aRsb; wherein Rsaand Rsb are each independently selected from hydrogen or (1 -2C)alkyl and integer s is 0, 1 or 2.

[0082] Particular compounds of the invention include, for example, compounds of the formula I, or pharmaceutically acceptable salts, hydrates and / or solvates thereof, wherein, unless otherwise stated, each of Ri, R2, R3, R4, Rs, X, Y, Z, RXi, RX2, RYI, RY2, bond a and any associated sub groups, have any of the meanings defined hereinbefore or in any of paragraphs (1) to (44) hereinafter:(1) R1 is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2 or 3;each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXB1)C(O)- or -N(RXB1)-, wherein RXB1is selected from hydrogen and (1-2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQiRQ2]n-, -[CRQ1RQ2]n-(3-10C)cycloalkyl, -[CRQiRQ2]n-(3 to 10-membered heterocyclyl), - [CRaiRQ2]n-aryl or -[CRaiRQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQI and RQ2 are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, N(RQS)RQ4, C(O)RQS, C(O)ORQ3, OC(O)RQ3, C(O)N(RQ3)RQ4 or N(RQS)C(O)RQ4; wherein RQS and RQ4 are each independently selected from H or (1 -2C)alkyl.(2) Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RLI and RL2 is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)- or-N(Rxsi)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQiRQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQiRQ2]n-(3 to 6-membered heterocyclyl), - [CRoiRQ2]n-phenyl or -[CRaiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; anddRQ1and RQ2are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl.(3) Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXB1)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQiRQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQ1RQ2]n-(3 to 6-membered heterocyclyl), - [CRQiRQ2]n-phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; andRQ1and RQ2are each independently selected from hydrogen or (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from hydrogen or methyl. (4) Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or -[CRL1RL2]-, wherein:each occurrence of RL1and RL2is independently selected from hydrogen or methyl;XBis absent or is selected from the group consisting of -O-, -C(O)N(RXB1)-, wherein RXBI is selected from hydrogen and methyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQiRQ2]n- (3-6C)cycloalkyl, -[CRQiRQ2]n-(4 to 6-membered heterocyclyl), -[CRQiRQ2]n- phenyl or -[CRaiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0 or 1; andRQ1and RQ2are each independently selected from hydrogen and methyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl.(5) Ri is a group of the formula:-LB-XB-QBwherein:LBis absent or -[CRL1RL2]-, wherein each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXBI)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, 3 to 6-membered heterocyclyl (e.g. oxetane, azetidine, 1,3- dioxolane or morpholine), phenyl or 5 or 6-membered heteroaryl; wherein:any QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy.(6) Ri is selected from (1-6C)alkyl, (1-6C)hydroxyalkyl, (1- 6C)haloalkyl, -(CH2)O-IC(0)N(RXBI)RQB, 5- or 6-membered heteroaryl (e.g. pyridyl), phenyl, (4-8-membered)heterocyclyl or-[CH2]-(4- to 8-membered)heterocyclyl, wherein (1 -6C)alkyl is optionally substituted with one or more substituents selected from (1-4C)alkoxy, (1-4C)alkoxy, hydroxy, (1-4C)alkoxy, cyano or N(RXBI)RQB; and any 5- or 6-membered heteroaryl (e.g. pyridyl), phenyl, (4-8- membered)heterocyclyl or -[CH2]-(4- to 8-membered)heterocyclyl is optionallysubstituted with one or more substituents selected from (1-2Calkyl), halo, (1- 4C)alkoxy, (1-4C)haloalkoxy, hydroxy, cyano or N(RXBi)RQB; wherein RXBI and RQBare each independently selected from hydrogen or (1 -2C)alkyl.(7) Ri is selected from (1-6C)alkyl, (1-6C)hydroxyalkyl, (1-6C)haloalkyl or C(O)N(RXBI)RQB, wherein (1-6C)alkyl is optionally substituted with one or more substituents selected from (1-2C)alkoxy, hydroxy, cyano or N(RXBI)RQB; wherein RXBI and RQBare each independently selected from hydrogen or methyl.(8) Ri is selected from (1-4C)alkyl, (1-4C)hydroxyalkyl, (1-4C)haloalkyl or C(O)N(RXBi)RQB, wherein (1-4C)alkyl is optionally substituted with one or more substituents selected from (1-2C)alkoxy or cyano;wherein any (1 -4C)alkyl, (1-4C)hydroxyalkyl or (1-4C)haloalkyl comprises a branched alkyl group (e.g. an isopropyl group).(9) Ri is a group of the formula:wherein LBis absent or -[CH2]-;Ria is selected from hydrogen, methyl, halo, hydroxy, cyano, methoxy.(10) Ri is a group of the formula:wherein LBis absent or -[CH2]-;Ria is selected from hydrogen or hydroxy.(11) Ri is a group with a formula selected from:P393348WO(12) R2is selected from hydrogen or methyl.(13) R2is hydrogen.(14) R3is selected from hydrogen or methyl.(15) R3is hydrogen.(16) bond a is either a single or a double bond, and wherein:when bond a is a single bond:X is -CH2-, andY is selected from -C(RYI)(RY2)- or-C(=0)-; orwhen bond a is a double bond:X is -CH- andY is -C(RY1)-;wherein:RYI and RY2 are each independently selected from hydrogen or (1-2C)alkyl; oror RYI and RY2 are linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring.(17) bond a is a single bond and:X is -CH2-, andY is selected from -C(RYI)(RY2)-;wherein:RYI and RY2 are each independently selected from hydrogen or methyl; orRYI and RY2 are linked such that, together with the carbon atom to which they are attached, they form a cyclopropyl ring.(18) R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-4C)alkyl (e.g. CH3or CD3), (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, -[CH2]r-(3-6C)cycloalkyl, - [CH2]r-(3- to 7-membered)heterocyclyl, -[CH2]r-phenyl or -[CH2]r-(5- or 6-membered) heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or (1-2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.(19) R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-3C)alkyl (e.g. CH3or CD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3-6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or6-membered)heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or (1-2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.(20) R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-3C)alkyl (e.g. CH3or CD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3-6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or6-membered)heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or methyl; any alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.(21) R4is selected from hydrogen, F or Cl, NR4aR4b, (1 -2C)alkyl (e.g. CH3or CD3), methoxy, (1-2C)haloalkyl, (3-4C)cycloalkyl, (4- to 5-membered)heterocyclyl or (5- or 6-membered)heteroaryl;wherein:each of R4aand R4b is independently selected from hydrogen or methyl; any alkyl, cycloalkyl, heterocyclyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino;(22) R4is methyl.(23) Z is selected from -C(Rz2)(Rzs)-, -O-, - or -NRzi, wherein:Rzi is selected from hydrogen or methyl; andRzz and RZ3are independently selected from hydrogen or methyl. (24) Z is selected from -CH2-, -O- or -NRzi; wherein Rzi is selected from hydrogen or methyl.(25) Z is -O-.(26) R5is selected from phenyl, 5- or 6-membered heteroaryl, ora bicyclic heteroaryl (e.g. a bicyclic heteroaryl comprising a phenyl ring fused to a 4- to 6 membered heterocyclic ring, an indole or an indazole);wherein R5is optionally substituted by one or more substituents R, wherein each RA is independently selected from: halo, hydroxy, cyano, (1 -4C)alkyl, (1- 4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, (3-6C)cycloalkyl, (3-6- membered)heterocyclyl and NRsaRsb; wherein Rsa and Rsb are each independently selected from hydrogen or methyl.(27) Rs is selected from phenyl, pyridyl, or a phenyl ring fused to a 4- to 6 membered heterocyclic ring;wherein R5is optionally substituted by one or more substituents RA, wherein each RAis independently selected from: halo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6- membered)heterocyclyl(28) Rs is a group of the formula:wherein a is an integer selected from 0, 1, 2, 3 or 4;each occurrence of RAis independently as defined anywhere herein.(29) Rs is a group of the formula:wherein a is an integer selected from 0, 1, 2, 3 or 4; andeach occurrence of R is independently selected from: halo, hydroxy, cyano, (1-2C)alkyl, (1 -2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6-membered)heterocyclyl;optionally wherein each occurrence of RA is independently selected from fluoro, chloro, hydroxy, cyano, or methoxy;further optionally wherein each occurrence of R is independently selected from fluoro or chloro.(30) R5is a group of the formula:wherein a is an integer selected from 0, 1, 2, 3 or 4; andeach occurrence of RA is independently selected from fluoro, chloro, hydroxy, cyano, or methoxy.(31) R5is a group of the formula:wherein a is an integer selected from 0, 1, 2 or 3; andeach occurrence of RA is independently selected from fluoro, chloro, hydroxy, cyano, or methoxy.(32) Rs is a group of the formula:wherein:a is an integer selected from 0, 1 or 2;each occurrence of R is independently as defined anywhere herein; at least one occurrence of RA is in the meta position.(33) R5is a group of the formula:each of RAMI, RAM2, RAO and RAP are independently selected from hydrogen, fluoro and chloro;wherein at least one of RAMI, RAM2, RAO and RAP is not hydrogen.(34) R5is a group of the formula:each of RAMI, RAO and RAP are independently selected from hydrogen, fluoro and chloro; andRAM2 is selected from fluoro and chloro.(35) R5is a group with a formula selected from:each of RAO and RAP are independently selected from hydrogen, fluoro and chloro; RAMI is selected from fluoro and chloro; andRAM2 is selected from fluoro and chloro.(36) R5is a group with a formula selected from:each of RAO and RAP are independently selected from hydrogen, fluoro and chloro; RAM is selected from fluoro and chloro;optionally wherein at least one of RAO and RAP is hydrogen, and the other is selected from fluoro and chloro.(37) Rxi and RX2 are each independently selected from hydrogen, halo, hydroxy, (1- 3C)alkyl or (1 -3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy;or Rxi and Rx2 are linked such that, together with the carbon atom to which they are attached, form a (3-6C)cycloalkyl ring.(38) Rxi and RX2 are each independently selected from hydrogen, halo, hydroxy, (1- 3C)alkyl or (1-3C)alkoxy.(39) Rxi and Rx2 are each independently selected from hydrogen, halo, hydroxy, methyl or methoxy.(40) Rxi and Rx2 are each independently selected from hydrogen or methyl.(41) Rxi and RX2 are hydrogen.(42) RYI and RY2 are each independently selected from hydrogen or (1 -2C)alkyl; or or RYI and RY2 are linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring.(43) RYI and RY2 are each independently selected from hydrogen or methyl.(44) RYI and RY2 are hydrogen.

[0083] Suitably, a heteroaryl or heterocyclyl group as defined herein is a monocyclic heteroaryl or mono, bicyclic or bridged heterocyclyl group comprising one, two or three heteroatoms selected from N, O or S.

[0084] Suitably, a heteroaryl is a 5- or 6-membered heteroaryl ring comprising one, two or three heteroatoms selected from N, O or S.

[0085] Suitably, a heterocyclyl group is a 4-, 5-, 6-, 7-, 8- or 9-membered heterocyclyl ring comprising one, two or three heteroatoms selected from N, O or S. Most suitably, a heterocyclyl group is a 5-, 6- or 7-membered monocyclic or bicyclic ring comprising one, two or three heteroatoms selected from N, O or S [e.g. morpholinyl (e.g. 4-morpholinyl), pyridinyl, piperazinyl, homopiperazinyl or pyrrolidinonyl].

[0086] Suitably, an aryl group is phenyl.

[0087] Suitably, Ri is as defined in any one of paragraphs (1) to (11) or (11a) above. More suitably, Ri is as defined in any one of paragraphs (6) to (11) or (11a) above. Most suitably, Ri is as defined in paragraph (11 ) or (11 a) above.

[0088] Suitably, R2is as defined in paragraph (12) or (13) above. More suitably, R2is as defined in paragraph (13) above.

[0089] Suitably, R3 is as defined in paragraph (14) or (15) above. More suitably, R3 is as defined in paragraph (15) above.

[0090] Suitably, bond a is as defined in paragraph (16) or (17) above. More suitably, bond a is as defined in paragraph (17).

[0091] Suitably, X is as defined in paragraph (16) or (17) above. More suitably, X is as defined in paragraph (17).

[0092] Suitably, Y is as defined in paragraph (16) or (17) above. More suitably, Y is as defined in paragraph (17).

[0093] Suitably, R4is as defined in any one of paragraphs (18) to (22) above. More suitably, R4is as defined in any one of paragraphs (20) to (22) above. Most suitably, R4is as defined in paragraph (22) above.

[0094] Suitably, Z is as defined in any one of paragraphs (23) to (25) above. More suitably, Z is as defined in paragraph (24) or (25) above. Most suitably, Z is as defined in paragraph (25) above.

[0095] Suitably, R5is as defined in any one of paragraphs (26) to (36) above. More suitably, R5is as defined in any one of paragraphs (32) to (36) above. Most suitably, R5is as defined in paragraph (35) or (36) above.

[0096] Suitably, RX1and RX2are as defined in any one of paragraphs (37) to (41) above. More suitably, RX1and RX2are as defined in any one of paragraphs (39) to (41) above. Most suitably, RX1and RX2are as defined in paragraph (41) above.

[0097] Suitably, RY1and RY2are as defined in any one of paragraphs (42) to (44) above. More suitably, RY1and RY2are as defined in paragraph (43) or (44) above. Most suitably, RY1and RY2are as defined in paragraph (44) above.

[0098] In an embodiment of the compounds of formula (I):Ri is as defined in any one of paragraphs (1) to (11) or (11a) above;R2 is as defined in paragraph (12) or (13) above;R3 is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (18) to (22) above;Z is as defined in any one of paragraphs (23) to (25) above; andR5is as defined in any one of paragraphs (26) to (36) above.

[0099] In an embodiment of the compounds of formula (I):R1 is as defined in any one of paragraphs (6), (7), (8), (9), (10), (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;R3is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (18) to (22) above;Z is as defined in any one of paragraphs (23) to (25) above; andR5is as defined in any one of paragraphs (26) to (36) above.

[0100] In an embodiment of the compounds of formula (I):Ri is as defined in any one of paragraphs (6) to (11) or (11a) above; R2is as defined in paragraph (12) or (13) above;Rs is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (20) to (22) above;Z is as defined in paragraph (24) or (25) above; andR5is as defined in any one of paragraphs (33) to (36) above.

[0101] In an embodiment of the compounds of formula (I):Ri is as defined in any one of paragraphs (9), (10) or (11) or (11a) above; R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andR5is as defined in any one of paragraphs (34), (35) or (36) above.

[0102] In an embodiment of the compounds of formula (I):Ri is as defined in any one of paragraphs (9), (10) or (11) or (11a) above; R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in paragraph (36) above.

[0103] In an embodiment of the compounds of formula (I):Ri is as defined in paragraph (11 ) or (11 a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andR5is as defined in any one of paragraphs (34), (35) or (36) above.

[0104] In an embodiment of the compounds of formula (I):R1 is as defined in paragraph (11 ) or (11 a) above;R2 is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andR5is as defined in paragraph (36) above.

[0105] In a particular embodiment, the compounds have the structural formula (II) (a subdefinition of formula (I)) shown below:wherein R1, R2, R3, R4, R5, X, Y, Z and bond a are as defined herein, or a pharmaceutically acceptable salt thereof.

[0106] In an embodiment of the compounds of formula (II):R1 is as defined in any one of paragraphs (1) to (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;Rs is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (18) to (22) above;Z is as defined in any one of paragraphs (23) to (25) above; andR5is as defined in any one of paragraphs (26) to (36) above.

[0107] In an embodiment of the compounds of formula (II):Ri is as defined in any one of paragraphs (6), (7), (8), (9), (10), (11) or (11a) above; R2is as defined in paragraph (12) or (13) above;Rs is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (18) to (22) above;Z is as defined in any one of paragraphs (23) to (25) above; andRs is as defined in any one of paragraphs (26) to (36) above.

[0108] In an embodiment of the compounds of formula (II):Ri is as defined in any one of paragraphs (6) to (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;R3is as defined in paragraph (14) or (15) above;bond a is as defined in paragraph (16) or (17) above;X is as defined in paragraph (16) or (17) above;Y is as defined in paragraph (16) or (17) above;R4is as defined in any one of paragraphs (20) to (22) above;Z is as defined in paragraph (24) or (25) above; andRs is as defined in any one of paragraphs (33) to (36) above.

[0109] In an embodiment of the compounds of formula (II):Ri is as defined in any one of paragraphs (9), (10) or (11) or (11a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0110] In an embodiment of the compounds of formula (II):Ri is as defined in paragraph (11a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0111] In an embodiment of the compounds of formula (II):R1 is as defined in any one of paragraphs (9), (10) or (11) above; R2 is as defined in paragraph (13) above;R3 is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in paragraph (36) above.

[0112] In an embodiment of the compounds of formula (II):R1 is as defined in paragraph (11 ) or (11 a) above;R2is as defined in paragraph (13) above;R3 is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0113] In an embodiment of the compounds of formula (II):R1 is as defined in paragraph (11 ) or (11 a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;bond a is as defined in paragraph (17) above;X is as defined in paragraph (17) above;Y is as defined in paragraph (17) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andR5is as defined in paragraph (36) above.

[0114] In a particular embodiment, the compounds have the structural formula (III) (a subdefinition of formula (I)) shown below:2(III)wherein R1, R2, R3, R4and R5are as defined herein, or a pharmaceutically acceptable salt thereof.

[0115] In an embodiment of the compounds of formula (III):R1 is as defined in any one of paragraphs (1) to (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;R3is as defined in paragraph (14) or (15) above;R4is as defined in any one of paragraphs (18) to (22) above; andR5is as defined in any one of paragraphs (26) to (36) above.

[0116] In an embodiment of the compounds of formula (III):R1 is as defined in any one of paragraphs (6), (7), (8), (9), (10), (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;R3is as defined in paragraph (14) or (15) above;R4is as defined in any one of paragraphs (18) to (22) above; andR5is as defined in any one of paragraphs (26) to (36) above.

[0117] In an embodiment of the compounds of formula (III):R1 is as defined in any one of paragraphs (6) to (11) or (11a) above;R2is as defined in paragraph (12) or (13) above;R3is as defined in paragraph (14) or (15) above;R4is as defined in any one of paragraphs (20) to (22) above; andRs is as defined in any one of paragraphs (33) to (36) above.

[0118] In an embodiment of the compounds of formula (III):R1 is as defined in any one of paragraphs (9), (10), (11) or (11a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0119] In an embodiment of the compounds of formula (III):Ri is as defined in any one of paragraphs (9), (10), (11) or (11a) above; R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above; andRs is as defined in paragraph (36) above.

[0120] In an embodiment of the compounds of formula (III):Ri is as defined in paragraph (10) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0121] In an embodiment of the compounds of formula (III):Ri is as defined in paragraph (10) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in paragraph (36) above.

[0122] In an embodiment of the compounds of formula (III):Ri is as defined in paragraph (11 ) or (11 a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above; andRs is as defined in any one of paragraphs (34), (35) or (36) above.

[0123] In an embodiment of the compounds of formula (III):Ri is as defined in paragraph (11 ) or (11 a) above;R2is as defined in paragraph (13) above;R3is as defined in paragraph (15) above;R4is as defined in paragraph (22) above;Z is as defined in paragraph (25) above; andRs is as defined in paragraph (36) above.

[0124] Particular compounds of the present invention include any of the compounds described in the example section of the present application, or a pharmaceutically acceptable pharmaceutically acceptable salt, hydrate or solvate thereof, and, in particular, any of the following:trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (fluoromethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;(R)-(6-(3-chlorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(oxetan-3-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2- b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-cyclopropyl-2, 3-dihydro-1 H-pyrrolo[3, 2-b]pyridin-1 - yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-4-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(hydroxymethyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-ethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methyl-d3)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans- (6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -y I) (3-(2- (oxetan-3-yloxy)propan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl) methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2,2,2-trifluoroethyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-2-(3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-2-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;2-((2S,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;2-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;((2R,3R)-3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-2-(3-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl) methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-4-yl)oxiran-2-yl)methanone;trans-(3-(tert-butyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-4-morpholinophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(3-(2-(benzyloxy)propan-2-yl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-cyclopropyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-4-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-phenyloxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-3-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-cyclopropyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-isopropyloxiran-2-yl)methanone;trans-(3-cyclopropyloxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isopropoxymethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)azetidine-3-carbonitrile;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(fluoromethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(fluoromethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)-3-methylazetidine-3-carbonitrile;trans-(6-(2,6-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;trans-(3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;3-((5-methyl-1-((2R,3S)-3-methyloxirane-2-carbonyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(benzo[d][1,3]dioxol-5-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluoro-3-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-fluoro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;trans-3-((1-(3-(difluoromethyl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-(6-((3,4-difluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)(methyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methoxy-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorophenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6'-(3-chloro-4-fluorobenzyl)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-2,2,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6'-(4-fluorophenoxy)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;Cis-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl isobutyrate;trans-N-((3-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)acetamide;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxycyclobutyl)oxiran-2-yl)methanone;(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(3-hydroxyoxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(4-hydroxytetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((S)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(hydroxymethyl)oxiran-2-yl)methanone;(R)-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-3-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-bromophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-7-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(2,3,4-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(2R,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;trans-(6-(3-(difluoromethyl)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-(fluoromethyl)phenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-bromophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-5-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3-(trifluoromethoxy)phenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3,4,5-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-cyclopropyl-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-dichlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-(difluoromethoxy)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-5-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-5-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(6-(benzo[d][1,3]dioxol-4-yloxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2S,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-fluoro-2-methylpropyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (morpholine-4-carbonyl)oxiran-2-yl)methanone;trans-(3-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(quinolin-7-yloxy)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2R,3S)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-3-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3- (2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-2-fluoro-6-((5-methyl-1-(3-(morpholinomethyl)oxirane-2-carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-3-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- (pyrimidin-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyrimidin-5-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((2-fluoropyridin-4-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (3-fluoropyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-azetidin-1-yl(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (3-methylpyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyrimidin-5-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (pyrimidin-2-yl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((5-fluoropyridin-3-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(5-methyl-6-(pyridin-3-yloxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone; ortrans-(6-((3-chlorophenyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone.

[0125] Further compounds of the present invention include any of the compounds described in the example section of the present application, or a pharmaceutically acceptable pharmaceutically acceptable salt, hydrate or solvate thereof, and, in particular, any of the following:trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(fluoromethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;(R)-(6-(3-chlorobenzyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(oxetan-3-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl) methanone;trans-(6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(dimethylamino)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl) methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-5-yl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl) methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-cyclopropyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-4-yl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl) methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(hydroxymethyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl) methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-ethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methyl-d3)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans- (6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-(oxetan- 3-yloxy)propan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl) methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2,2,2-trifluoroethyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-2-(3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-2-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(oxetan- 3-ylmethyl)oxiran-2-yl) methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;2-((2S,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;2-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;((2R,3R)-3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-2-(3-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isoxazol-4-yl)oxiran-2-yl)methanone;trans-(3-(tert-butyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-4-morpholinophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(3-(2-(benzyloxy)propan-2-yl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-cyclopropyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1H-pyrazol-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin- 3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin- 2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin- 3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin- 4-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin- 2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-phenyloxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan- 3-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1H-pyrazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan- 3-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isoxazol-5-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-3-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-cyclopropyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isoxazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-isopropyloxiran-2-yl)methanone;trans-(3-cyclopropyloxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isopropoxymethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)azetidine-3-carbonitrile;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isopropoxymethyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- (fluoromethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3- (fluoromethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)-3-methylazetidine-3-carbonitrile;trans-(6-(2,6-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;trans-(3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;3-((5-methyl-1-((2R,3S)-3-methyloxirane-2-carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(benzo[d][1,3]dioxol-5-yloxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(4-fluoro-3-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(3-fluoro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;trans-3-((1-(3-(difluoromethyl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)- N, N-dimethyloxirane-2-carboxamide;trans-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)- N, N-dimethyloxirane-2-carboxamide;(2S,3S)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-(6-((3,4-difluorophenyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)(methyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methoxy-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6'-(3-chloro-4-fluorobenzyl)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-2,2,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone; or(6'-(4-fluorophenoxy)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)((2R,3S)-3-methyloxiran-2-yl)methanone.

[0126] Further particular compounds of the present invention include any of the compounds described in the example section of the present application, or a pharmaceutically acceptable pharmaceutically acceptable salt, hydrate or solvate thereof, and, in particular, any of the following:cis-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl isobutyrate;trans-N-(((2S)-3-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)acetamide;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)(3-(1 -hydroxycyclobutyl)oxiran-2-yl)methanone;(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(3-hydroxyoxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(4-hydroxytetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- ((S)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- ((R)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((R)-1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;(R)-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran- 2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -y I) (3-(1 -hydroxyethyl)oxiran-2-yl)methanone;trans-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-3-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)- 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-bromophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-7-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(2,3,4-trifluorophenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;(2R,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;trans-(6-(3-(difluoromethyl)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-(fluoromethyl)phenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-bromophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-5-((1-((3R)-3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3-(trifluoromethoxy)phenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3,4,5-trifluorophenoxy)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-cyclopropyl-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-dichlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-(difluoromethoxy)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-5-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-5-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-6-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(6-(benzo[d][1,3]dioxol-4-yloxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2S,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;trans-((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-((3S)-3-(2-fluoro-2-methylpropyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(morpholine-4-carbonyl)oxiran-2-yl)methanone;trans-((3R)-3-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(quinolin-7-yloxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2R,3S)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-3-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-((2R,3S)-3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-((2R,3S)-3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-2-fluoro-6-((5-methyl-1-((2R,3S)-3-(morpholinomethyl)oxirane-2-carbonyl)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-3-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine- 1 -carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- (pyrimidin-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrimidin-5-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((2-fluoropyridin-4-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-azetidin-1-yl(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(pyrimidin-5-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyrimidin-2-yl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((5-fluoropyridin-3-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(5-methyl-6-(pyridin-3-yloxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone; ortrans-(6-((3-chlorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((3S)-3-ethyloxiran-2-yl)methanone.

[0127] The various functional groups and substituents making up the compounds of the formula (I) are typically chosen such that the molecular weight of the compound of the formula (I) does not exceed 1000. More usually, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650. More preferably, the molecular weight is less than 600 and, for example, is 550 or less.

[0128] A suitable pharmaceutically acceptable salt of a compound of the invention is, forexample, an acidaddition salt of a compound of the invention which is sufficiently basic, for example, an acidaddition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulfuric, phosphoric, trifluoroacetic, formic, citric methane sulfonate or maleic acid. In addition, a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a pharmaceutically acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris(2hydroxyethyl)amine.

[0129] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed “isomers”. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereomers” and those that are nonsuperimposable mirror images of each other are termed “enantiomers”. When a compound has an asymmetric center-, for example, it is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and is described by the R and S sequencing rules of Cahn and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or -levorotatory- (i.e., as (+) or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a “racemic mixture”.

[0130] The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R) or (S)stereoisomers or as mixtures thereof. Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are wellknown in the art (see discussion in Chapter 4 of “Advanced Organic Chemistry”, 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolution of a racemic form. Some of the compounds of the invention may have geometric isomeric centres (E and Z isomers). It is to be understood that the present invention encompasses all optical, diastereoisomers and geometric isomers and mixtures thereof that possess activity against MutSβ.

[0131] The present invention also encompasses compounds of the invention as defined herein which comprise one or more isotopic substitutions. For Example, H may be in any isotopic form, including1H,2H(D), and3H (T); C may be in any isotopic form, including12C,13C, and14C; and O may be in any isotopic form, including16O and18O; and the like.

[0132] It is also to be understood that certain compounds of the formula (I) may exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms that possess activity against MutSβ.

[0133] It is also to be understood that certain compounds of the formula I may exhibit polymorphism, and that the invention encompasses all such forms that possess activity against MutSβ.

[0134] Compounds of the formula I may exist in a number of different tautomeric forms and references to compounds of the formula I include all such forms. For the avoidance of doubt, where a compound can exist in one of several tautomeric forms, and only one is specifically described or shown, all others are nevertheless embraced by formula I. Examples of tautomeric forms include keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto / enol (illustrated below), imine / enamine, amide / imino alcohol, amidine / amidine, nitroso / oxime, thioketone / enethiol, and nitro / aci-nitro.Ilzo \ OH H+xO'— c-c' — c=c c=czI x / \H+ / \keto enol enolate

[0135] Compounds of the formula I containing an amine function may also form N-oxides. A reference herein to a compound of the formula I that contains an amine function also includes the N-oxide. Where a compound contains several amine functions, one or more than one nitrogen atom may be oxidised to form an N-oxide. Particular Examples of N-oxides are the N-oxides of a tertiary amine or a nitrogen atom of a nitrogen-containing heterocycle. N-Oxides can be formed by treatment of the corresponding amine with an oxidizing agent such as hydrogen peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm. 1977, 7, 509-514) in which the amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example, in an inert solvent such as dichloromethane.

[0136] The compounds of formula (I) may be administered in the form of a prodrug which is broken down in the human or animal body to release a compound of the invention. A pro-drug may be used to alter the physical properties and / or the pharmacokinetic properties of a compound of the invention. A pro-drug can be formed when the compound of the invention contains a suitable group or substituent to which a property-modifying group can be attached. Examples of pro-drugs include in vivo cleavable ester derivatives that may be formed at a carboxy group or a hydroxy group in a compound of the formula (I) and in-vivo cleavable amidederivatives that may be formed at a carboxy group or an amino group in a compound of the formula (I).

[0137] Accordingly, the present invention includes those compounds of the formula (I) as defined hereinbefore when made available by organic synthesis and when made available within the human or animal body by way of cleavage of a pro-drug thereof. Accordingly, the present invention includes those compounds of the formula I that are produced by organic synthetic means and also such compounds that are produced in the human or animal body by way of metabolism of a precursor compound, that is a compound of the formula (I) may be a synthetically-produced compound ora metabolically-produced compound.

[0138] A suitable pharmaceutically acceptable pro-drug of a compound of the formula (I) is one that is based on reasonable medical judgement as being suitable for administration to the human or animal body without undesirable pharmacological activities and without undue toxicity.

[0139] Various forms of pro-drug have been described, for example in the following documents:-a) Methods in Enzymology, Vol. 42, p. 309-396, edited by K. Widder, et al. (Academic Press, 1985);b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H. Bundgaard, Chapter 5 “Design and Application of Pro-drugs”, by H. Bundgaard p. 113-191 (1991);d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1-38 (1992);e) H. Bundgaard, et al., Journal of Pharmaceutical Sciences, 77, 285 (1988);f) N. Kakeya, et al., Chem. Pharm. Bull., 32, 692 (1984);g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, A. C. S. Symposium Series, Volume 14; andh) E. Roche (editor), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.

[0140] A suitable pharmaceutically acceptable pro-drug of a compound of the formula I that possesses a carboxy group is, for example, an in vivo cleavable ester thereof. An in vivo cleavable ester of a compound of the formula I containing a carboxy group is, for example, a pharmaceutically acceptable ester which is cleaved in the human or animal body to produce the parent acid. Suitable pharmaceutically acceptable esters for carboxy include C1-6alkyl esters such as methyl, ethyl and fe / t-butyl, C1-6alkoxymethyl esters such as methoxymethyl esters, C1-6alkanoyloxymethyl esters such as pivaloyloxymethyl esters,3-phthalidyl esters, C3-8cycloalkylcarbonyloxy- C1-6alkyl esters such as cyclopentylcarbonyloxymethyl and 1 -cyclohexylcarbonyloxyethyl esters, 2-oxo-1,3-dioxolenylmethyl esters such as 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl esters and C1-6alkoxycarbonyloxy- C1-6alkyl esters such as methoxycarbonyloxymethyl and 1-methoxycarbonyloxyethyl esters.

[0141] A suitable pharmaceutically acceptable pro-drug of a compound of the Formula (I) that possesses a hydroxy group is, for example, an in vivo cleavable ester or ether thereof. An in vivo cleavable ester or ether of a compound of the formula I containing a hydroxy group is, for example, a pharmaceutically acceptable ester or ether which is cleaved in the human or animal body to produce the parent hydroxy compound. Suitable pharmaceutically acceptable ester forming groups for a hydroxy group include inorganic esters such as phosphate esters (including phosphoramidic cyclic esters). Further suitable pharmaceutically acceptable ester forming groups for a hydroxy group include C1-10alkanoyl groups such as acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups, C1-10alkoxycarbonyl groups such as ethoxycarbonyl, N, N -(C1-6)2carbamoyl, 2-dialkylaminoacetyl and 2-carboxyacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(C1-4alkyl)piperazin-1-ylmethyl. Suitable pharmaceutically acceptable ether forming groups for a hydroxy group include a-acyloxyalkyl groups such as acetoxymethyl and pivaloyloxymethyl groups.

[0142] A suitable pharmaceutically acceptable pro-drug of a compound of the formula (I) that possesses a carboxy group is, for example, an in vivo cleavable amide thereof, for example an amide formed with an amine such as ammonia, a C1-4alkylamine such as methylamine, a (C1-4alkyl)2amine such as dimethylamine, N-ethyl-N-methylamine or diethylamine, a C1-4alkoxy- C2-4alkylamine such as 2-methoxyethylamine, a phenyl-C1-4alkylamine such as benzylamine and amino acids such as glycine or an ester thereof.

[0143] A suitable pharmaceutically acceptable pro-drug of a compound of the formula I that possesses an amino group is, for example, an in vivo cleavable amide derivative thereof. Suitable pharmaceutically acceptable amides from an amino group include, for example an amide formed with C1-10alkanoyl groups such as an acetyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl groups. Examples of ring substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N, N-dialkylaminomethyl, morpholinomethyl, piperazin-1 -ylmethyl and 4-(C1 -4alkyl)piperazin-1 -ylmethyl.

[0144] The in vivo effects of a compound of the formula (I) may be exerted in part by one or more metabolites that are formed within the human or animal body after administration of a compound of the formula (I). As stated hereinbefore, the in vivo effects of a compound of theformula (I) may also be exerted by way of metabolism of a precursor compound (a prodrug. Though the present invention may relate to any compound or particular group of compounds defined herein by way of optional, preferred or suitable features or otherwise in terms of particular embodiments, the present invention may also relate to any compound or particular group of compounds that specifically excludes said optional, preferred or suitable features or particular embodiments.

[0145] Suitably, the present invention excludes any individual compounds not possessing the biological activity defined herein.Synthesis

[0146] The compounds of the present invention can be prepared by any suitable technique known in the art. Particular processes for the preparation of the compounds of the invention are described in the Example section below.

[0147] In the description of the synthetic methods described herein and in any referenced synthetic methods that are used to prepare the starting materials, it is to be understood that all proposed reaction conditions, including choice of solvent, reaction atmosphere, reaction temperature, duration of the experiment and workup procedures, can be selected by a person skilled in the art.

[0148] It is understood by one skilled in the art of organic synthesis that the functionality present on various portions of the molecule must be compatible with the reagents and reaction conditions utilised.

[0149] It will be appreciated that during the synthesis of the compounds of the invention in the processes defined herein, or during the synthesis of certain starting materials, it may be desirable to protect certain substituent groups to prevent their undesired reaction. The skilled chemist will appreciate when such protection is required, and how such protecting groups may be put in place, and later removed.

[0150] For examples of protecting groups see one of the many general texts on the subject, for example, ‘Protective Groups in Organic Synthesis’ by Theodora Green (publisher: John Wiley & Sons). Protecting groups may be removed by any convenient method described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with the minimum disturbance of groups elsewhere in the molecule.

[0151] Thus, if reactants include, for example, groups such as amino, carboxy or hydroxy it may be desirable to protect the group in some of the reactions mentioned herein.

[0152] By way of example, a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or tbutoxycarbonyl group, anarylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection conditions forthe above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such as a tert-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulfuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladiumoncarbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

[0153] A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium, sodium hydroxide or ammonia. Alternatively, an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladiumoncarbon.

[0154] A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a tbutyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladiumoncarbon.

[0155] Resins may also be used as a protecting group.

[0156] The methodology employed to synthesise a compound of formula (I) will vary depending on the nature of R1, R2, R3, R4, R5, X, Y, Z and bond a and any substituent groups associated therewith. Suitable processes for their preparation are described further in the accompanying Examples.

[0157] Once a compound of formula (I) has been synthesised by any one of the processes defined herein, the processes may then further comprise one or more of the additional steps of:(i) removing any protecting groups present;(ii) converting the compound formula (I) into another compound of formula (I);(iii) forming a pharmaceutically acceptable salt, hydrate or solvate of the compound of formula I; and / or(iv) forming a prodrug of the compound of formula I.

[0158] An example of (ii) above is when a compound of formula (I) is synthesised and then one or more of the groups of R1, R2, R3, R4, R5, X, Y, Z and bond a may be further reacted to change the nature of the group and provide an alternative compound of formula (I).

[0159] The resultant compounds of formula (I) can be isolated and purified using techniques well known in the art.Biological Activity

[0160] The biological assay described in the example sectionmay be used to measure the pharmacological effects of the compounds of the present invention.

[0161] Although the pharmacological properties of the compounds of formula I vary with structural change, as expected, the compounds of the invention were found to be active in the assay described in the Biological Examples.

[0162] In general, in terms of MutSβ inhibitory activity, preferred compounds of the invention demonstrate an IC50 of 5 pM or less in the assay described in Biological Example A, with more preferred compounds of the invention demonstrating an IC50 of 1 pM or less and the most preferred compounds of the invention demonstrating an IC50 of 0.5 pM or less.

[0163] In general, in terms of activity, preferred compounds of the invention demonstrate a minimum effective concentration of 1 pM or less in the assay described in Biological Example B, with more preferred compounds of the invention demonstrating a minimum effective concentration of 0.5 pM or less and the most preferred compounds of the invention demonstrating a minimum effective concentration of 0.1 pM or less.

[0164] The following compounds were made and tested, and did not show an IC50 of 5 pM or less in the assay described in Biological Example A:cis-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2- hydroxypropan-2-yl)oxiran-2-yl)methanone;cis-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1- yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)-5-methyl-2,3-dihydro-1H- pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone; trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(imidazo[1,2-a]pyridin-7-yloxy)-5- methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(4-(trifluoromethoxy)phenoxy)- 2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(imidazo[1,5-a]pyridin-6-yloxy)-5- methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2-fluoro-3-(methoxymethyl)phenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2- b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((4-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1- yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(quinolin-7-yloxy)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2- b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;cis-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- phenyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2- methyl-1-morpholinopropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2- morpholinopropan-2-yl)oxiran-2-yl)methanone;rac-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1- yl)(3,3-dimethyloxiran-2-yl)methanone;rac-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1- yl)(2,3-dimethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(1 -methyl-1 H-pyrazol-3-yl)-2,3-dihydro-1 H- pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(1 -methyl-1 H-pyrazol-4-yl)-2,3-dihydro-1 H- pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methoxymethyl)-2,3-dihydro-1H-pyrrolo[3,2- b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(oxetan-3-yl)-2,3-dihydro-1H-pyrrolo[3,2- b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin- 1 -yl)(3-(morpholinomethyl)oxiran-2-yl)methanone; ortrans-(6-(2-fluoro-3-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin- 1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone.

[0165] In an embodiment of the invention, the compounds of Formula (I) defined herein do not include any of the compounds listed above, i.e. the compounds named above that did not show an IC5o of 10 pM or less in the assay described in Biological Example.Pharmaceutical Compositions

[0166] According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the invention as defined hereinbefore, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in association with a pharmaceutically acceptable diluent or carrier.

[0167] The compositions of the invention may be in a form suitable for oral use (for example as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), for topical use (for example as creams, ointments, gels, or aqueous or oily solutions or suspensions), for administration by inhalation (for example as a finely divided powder or a liquid aerosol), for administration by insufflation (for example as a finely divided powder) or for parenteral administration (for example as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular dosing or as a suppository for rectal dosing).

[0168] The compositions of the invention may be obtained by conventional procedures using conventional pharmaceutical excipients, well known in the art. Thus, compositions intended for oral use may contain, for example, one or more colouring, sweetening, flavouring and / or preservative agents.

[0169] An effective amount of a compound of the present invention for use in therapy is an amount sufficient to treat or prevent a proliferative condition referred to herein, slow its progression and / or reduce the symptoms associated with the condition.

[0170] The amount of active ingredient that is combined with one or more excipients to produce a single dosage form will necessarily vary depending upon the individual treated and the particular route of administration. For Example, a formulation intended for oral administration to humans will generally contain, for example, from 0.5 mg to 0.5 g of active agent (more suitably from 0.5 to 100 mg, for example from 1 to 30 mg) compounded with an appropriate and convenient amount of excipients which may vary from about 5 to about 98 percent by weight of the total composition.

[0171] The size of the dose for therapeutic or prophylactic purposes of a compound of the formula I will naturally vary according to the nature and severity of the conditions, the age and sex of the animal or patient and the route of administration, according to well-known principles of medicine.

[0172] In using a compound of the invention for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg / kg to 75 mg / kg body weight is received, given if required in divided doses. In general lower doses will be administered when a parenteral route is employed. Thus, for example, for intravenous orintraperitoneal administration, a dose in the range, for example, 0.1 mg / kg to 30 mg / kg body weight will generally be used. Similarly, for administration by inhalation, a dose in the range, for example, 0.05 mg / kg to 25 mg / kg body weight will be used. Oral administration may also be suitable, particularly in tablet form. Typically, unit dosage forms will contain about 0.5 mg to 0.5 g of a compound of this invention.Therapeutic Uses and Applications

[0173] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0174] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein, for use in the treatment of any of the diseases discussed herein.

[0175] The present invention provides compounds that function as MutSβ inhibitors. Thus, the compounds of the invention can be used to inhibit somatic expansion of simple nucleotide repeats associated with MutSβ activity. The compounds of the present invention therefore have particular application in treating, preventing, or delaying the onset of a repeat expansion disease or disorder in a subject.

[0176] MutSβ activity is implicated in the somatic instability of expanded simple nucleotide repeats, which leads to further expansion. The inhibition of MutSβ activity may therefore allow the treatment of diseases related to somatic expansion of expanded simple nucleotide repeats, such as repeat expansion diseases or disorders. Thus, by virtue of their activity against MutSβ, the compounds of the present invention may be used as an agent to inhibit somatic expansion in the treatment, prevention, or delaying of the onset of repeat expansion diseases or disorders.

[0177] In the present invention, it will be understood that reference to inhibition of somatic expansion encompasses reducing or preventing somatic instability of expanded simple nucleotide repeats, and also encompasses the slowing or stopping of somatic expansion of expanded simple nucleotide repeats.

[0178] According to a further aspect of the present invention, there is provided a method of inhibiting MutSβ activity in vitro, ex vivo or in vivo, said method comprising contacting a cell with an effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein. Suitably, the method comprises the selective inhibition of MutSβ activity in vitro, ex vivo or in vivo.

[0179] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use inthe inhibition of MutSβ activity, e.g. in cellular systems. The inhibition may be the selective inhibition of MutSβ activity.

[0180] According to a further aspect of the present invention, there is provided a use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament forthe inhibition of MutSβ activity, e.g. in cellular systems.

[0181] According to a further aspect of the present invention, there is provided a method of inhibiting somatic expansion of expanded simple nucleotide repeats, said method comprising administering to said subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein. The method may be performed in a subject or in a cellular assay system.

[0182] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in inhibiting somatic expansion of expanded simple nucleotide repeats in a subject (e.g. in the treatment of a repeat expansion disease or disorder).

[0183] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for inhibiting somatic expansion of expanded simple nucleotide repeats in a subject (e.g. in the treatment of a repeat expansion disease or disorder).

[0184] According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof in inhibiting somatic expansion of expanded simple nucleotide repeats in a cellular assay system.

[0185] According to a further aspect of the present invention, there is provided a method of treating a disease or condition in which MutSβ activity is implicated in a patient in need of such treatment, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0186] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in the treatment of a disease or condition in which MutSβ activity is implicated.

[0187] According to a further aspect of the present invention, there is provided a use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament forthe treatment of a disease or condition in which MutSβ activity is implicated.

[0188] The disease or condition in which MutSβ activity is implicated may be a diseaserelated to somatic expansion of expanded simple nucleotide repeats, such as a repeat expansion disease or disorder.

[0189] According to a further aspect of the present invention, there is provided a method of treating a repeat expansion disease or disorder in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0190] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of a repeat expansion disease or disorder.

[0191] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a repeat expansion disease or disorder.

[0192] Repeat expansion diseases (REDs) are caused by pathogenic expansions of simple nucleotide repeats within coding and non-coding regions of different genes. Repeat expansion diseases include but are not limited to: benign adult familial myoclonic epilepsy (BAFME); brachydactyly and cleidocranial dysplasia (BCCD); blepharophimosis, ptosis and epicanthus inversus (BPES); Baratela-Scott syndrome (BSS); cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS); congenital central hypoventilation syndrome (CCHS); dentatorubropallidoluysian atrophy (DRPLA); early infantile epileptic encephalopathy type 1 (EIEE1); familial adult myoclonic epilepsy (FAME); FGF14-linked Parkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); Dentatorubral pallidoluysian atrophy; fragile XE syndrome (FRAXE);; Friedreich ataxia (FRDA) frontotemporal dementia / amyotrophic lateral sclerosis (FTD / ALS); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); global development delay, progressive ataxia and elevated glutamine (GDPAG); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); hand-foot-genital syndrome (HFGS); holoprosencephaly type 5 (HPE5); mental retardation with isolated growth hormone deficiency (MRGH); myotonic dystrophy type 1 (DM1); myotonic dystrophy type 2 (DM2); progressive myoclonus epilepsy type 1 or Unverricht-Lundborg diseae (EPM1); neuronal intranuclear inclusion disease (NIID); oculopharyngodistal myopathy type 1 (OPDM1); oculopharyngodistal myopathy type 2 (OPDM2); oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 10, 12, 17, 27B, 31, 36, 37 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, SCA31, SCA36, SCA37); synpolydactyly (SPD); X-linkeddystonia parkinsonism (XDP); X-linked mental retardation and abnormal genitalia (XLAG); and X-linked mental retardation with or without growth hormone deficiency (XLMR, XLMRGHD).

[0193] The repeat expansion disease or disorder may be a coding repeat expansion disease, such as brachydactyly and cleidocranial dysplasia (BCCD); blepharophimosis, ptosis and epicanthus inversus (BPES); cleidocranial dysplasia (CCD); congenital central hypoventilation syndrome (CCHS); dentatorubropallidoluysian atrophy (DRPLA); early infantile epileptic encephalopathy type 1 (EIEE1); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); hand-foot-genital syndrome (HFGS); holoprosencephaly type 5 (HPE5); mental retardation with isolated growth hormone deficiency (MRGH); oculopharyngeal muscular dystrophy (OPMD); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 17 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA17); synpolydactyly (SPD); X-linked mental retardation and abnormal genitalia (XLAG); X-linked mental retardation with or without growth hormone deficiency (XLMR, XLMRGHD).

[0194] The repeat expansion disease or disorder may be a non-coding repeat expansion diseases include but are not limited to benign adult familial myoclonic epilepsy (BAFME); Baratela-Scott syndrome (BSS); cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS); myotonic dystrophy type 1 (DM1); myotonic dystrophy type 2 (DM2); progressive myoclonus epilepsy type 1 or Unverricht-Lundborg diseae (EPM1); familial adult myoclonic epilepsy (FAME); FGF14-linked Parkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE);; Friedreich ataxia (FRDA) frontotemporal dementia / amyotrophic lateral sclerosis (FTD / ALS); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); global development delay, progressive ataxia and elevated glutamine (GDPAG); neuronal intranuclear inclusion disease (NIID); oculopharyngodistal myopathy type 1 (OPDM1); oculopharyngodistal myopathy type 2 (OPDM2); oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1), spinocerebellar ataxias types 8, 10, 12, 27B, 31, 36, 37 (SCA8, SCA10, SCA12, SCA27B, SCA31, SCA36, SCA37); X-linked dystonia parkinsonism (XDP).

[0195] In certain embodiments, the repeat expansion disease or disorder is a triplet repeat disease or disorder, such as dentatorubropallidoluysian atrophy (DRPLA); FGF14-linked Parkinson’s disease; Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA); fragile X-associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X-associated tremor ataxia syndrome (FXTAS); Huntington’s disease (HD); Huntington disease-like 2 (HDL2); myotonic dystrophy type 1 (DM1); neuronal intranuclear inclusion disease (NIID)spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 17, (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA17). Suitably, the triplet repeat disease or disorder is Huntington’s disease (HD).

[0196] According to a further aspect of the present invention, there is provided a method of treating a triplet repeat disease or disorder in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0197] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the treatment of a triplet repeat disease or disorder.

[0198] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a triplet repeat disease or disorder.

[0199] According to a further aspect of the present invention, there is provided a method of treating Huntington’s disease in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0200] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of Huntington’s disease.

[0201] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of Huntington’s disease.

[0202] Suitably, the inhibition of somatic expansion of expanded simple nucleotide repeats allows the treatment of a repeat expansion disease or disorder in a subject who has already developed the disorder. The inhibition of somatic expansion of expanded simple nucleotide repeats may also be performed to prevent or slow the development of the disorder, for example in a patient who is carrying a disease allele for a repeat expansion disease or disorder. For example, the patient may have had a diagnostic test to say they are a repeat expansion disease or disorder gene carrier (for example, a Huntington Disease gene carrier), but who have not yet exhibited any signs or symptoms.

[0203] According to a further aspect of the present invention, there is provided a method for the inhibition of somatic expansion of expanded simple nucleotide repeats in a subject carrying a disease allele for a repeat expansion disease or disorder, said method comprising administering to said subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein.

[0204] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition as defined herein for use in the inhibition of somatic expansion of expanded simple nucleotide repeats in a subject carrying a disease allele for a repeat expansion disease or disorder.

[0205] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament forthe inhibition of somatic expansion of expanded simple nucleotide repeats in a subject carrying a disease allele for a repeat expansion disease or disorder.

[0206] The patient or subject to be treated is suitably a mammal, and more suitably a human.Routes of Administration

[0207] The compounds of the invention or pharmaceutical compositions comprising these compounds may be administered to a subject by any convenient route of administration, whether systemically / peripherally or topically (i.e., at the site of desired action).

[0208] Routes of administration include, but are not limited to, oral (e.g, by ingestion); buccal; sublingual; transdermal (including, e.g., by a patch, plaster, etc.); transmucosal (including, e.g., by a patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or insufflation therapy using, e.g., via an aerosol, e.g., through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by pessary); parenteral, for example, by injection, including subcutaneous, intradermal, intramuscular, intravenous, intra-arterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcuticular, intraarticular, subarachnoid, and intrasternal; by implant of a depot or reservoir, for example, subcutaneously or intramuscularly.Gene Editing

[0209] The compounds of the present invention may also find use in gene editing applications. In particular, the compounds are potentially useful for increasing the efficiency of gene editing techniques, especially gene editing techniques that are susceptibe to reduced efficiency due to host cell MMR factors.

[0210] It will be appreciated that the gene editing techniques defined herein may be carried in vivo, ex vivo or in vitro.

[0211] According to a further aspect of the present invention, there is provided a method of increasing the efficiency of a gene editing technique, the method comprising conducting the gene editing technique in the presence of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof. The efficiency of the gene editingtechnique may be increased by reducing the error rate.

[0212] According to a further aspect of the present invention, there is also provided a method of reducing the error rate of a gene editing technique, the method comprising conducting the gene editing technique in the presence of a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0213] Suitably, the gene editing technique referred to herein may be any suitable gene editing technique in which host cell mis-match repair (MMR) factors are known to decrease the efficiency of the gene editing. Suitable gene editing techniques include homology-directed repair (HDR), non-homologous end joining (NHEJ), ZFN (zinc finger nucleases), TALENs (Transcription activator like effector nucleases), CRISPR-Cas9 nucleases, CRISPR-Cas12 nucleases, base editing (fusion of catalytically dead dCas9 enzymes to DNA deaminases which enable single nucleotide substitutions), prime editing (fusion of a Cas9 nickase to a reverse transcriptase), PASTE (programmable addition via site-specific targeting elements which leverages prime editing to insert AttB sites and then facilitate serine integrase proteins to insert larger sequences), or any editing method using a single-stranded oligonucleotide (ssODN) as a template including nuclease-free editing methods.

[0214] According to a further aspect of the present invention, there is provided a method of prime editing, the method comprising contacting a cell with: (1) a Cas9 nickase to nick a nontarget strand; (2) a prime editing single guide RNA (pegRNA) to bind the target strand; (3) a reverse transcriptase to reverse transcribe from the 3’ end of the non-target strand according to the information provided by the pegRNA; and (4) a compound as defined herein, or a pharmaceutically acceptable salt, hydrate or solvate thereof.

[0215] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for gene editing in vitro, ex vivo or in vivo.

[0216] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use in gene editing in vitro, ex vivo or in vivo.

[0217] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, or a pharmaceutical composition as defined herein, for use in prime editing. According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, ora pharmaceutical composition as defined herein, for use in enhancing the efficiency of prime editing. Suitably, the compound of the invention or a pharmaceutically acceptable salt, hydrate or solvate thereof, is administered in combination with: (1) a Cas9 nickase to nick a non-target strand; (2) a prime editing single guide RNA (pegRNA) to bind the target strand; (3) a reverse transcriptase toreverse transcribe from the 3’ end of the non-target strand according to the information provided by the pegRNA.

[0218] According to a further aspect of the present invention, there is provided the use a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, for prime editing. According to a further aspect of the present invention, there is provided the use of a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, or a pharmaceutical composition as defined herein, for enhancing the efficiency of prime editing. Suitably, the compound of the invention or a pharmaceutically acceptable salt, hydrate or solvate thereof, is administered in combination with: (1) a Cas9 nickase to nick a non-target strand; (2) a prime editing single guide RNA (pegRNA) to bind the target strand; (3) a reverse transcriptase to reverse transcribe from the 3’ end of the non-target strand according to the information provided by the pegRNA.

[0219] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use as an agent to enhance the efficiency of prime editors.

[0220] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein as an agent to enhance the efficiency of prime editors.

[0221] According to a further aspect of the present invention, there is provided a method to enhance the efficiency of prime editors, the method comprising contacting a cell with a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, or a pharmaceutical composition as defined herein, and conducting the gene editing in the presence of said compound.

[0222] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use as an agent to reduce off-target editing (errors) in prime editing.

[0223] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein as an agent to reduce off-target editing (errors) in prime editing. Suitably, the use is in cellular systems.

[0224] According to a further aspect of the present invention, there is provided a method to enhance efficiency and reduce off-target editing (errors) in gene editing (e.g. prime editing), the method comprising contacting a cell with a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, or a pharmaceutical composition as defined herein, and conducting the gene editing in the presence of said compound.

[0225] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use asan agent to both enhance efficiency and reduce off-target editing (errors) in gene editing (e.g. prime editing).

[0226] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein as an agent to both enhance efficiency and reduce off-target editing (errors) in gene editing (e.g. prime editing). Suitably, the use is in cellular systems.

[0227] According to a further aspect of the present invention, there is provided a method to enhance the efficiency of prime editor therapeutics in vivo or ex vivo (e.g. allogeneic editing of hematopoietic cells), the method comprising contacting a cell with a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, or a pharmaceutical composition as defined herein, and conducting the gene editing in the presence of said compound.

[0228] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use as an agent to enhance the efficiency of prime editor therapeutics ex vivo (e.g. allogeneic editing of hematopoietic cells).

[0229] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein as an agent to enhance the efficiency of prime editor therapeutics ex vivo (e.g. allogeneic editing of hematopoietic cells).

[0230] According to a further aspect of the present invention, there is provided a compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein for use as an agent to enhance the efficiency of prime editor therapeutics in vivo.

[0231] In certain embodiments, the gene is in a cell, e.g. a mammalian cell, e.g. a human cell.

[0232] In certain embodiments, the cell is in a subject or patient, e.g. the subject is human.

[0233] In certain embodiments, the cell is present in vitro, ex vivo or in vivo.

[0234] In certain embodiments, the cell is in a cellular assay.

[0235] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein as an agent to inhibit mismatch repair in vitro, ex vivo or in vivo, for example in cellular systems.

[0236] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in testing an agent for the ability to inhibit ATP hydrolysis by MutSβ in the presence or absence of a suitable heteroduplex DNA substrate.

[0237] According to a further aspect of the present invention, there is provided the use of acompound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein, in testing an agent for the ability to inhibit ATP-dependent recruitment of MutLα or MutLβ or MutLγ by MutSβ.Combination Therapies

[0238] The present invention provides methods for the treatment of certain diseases or disorders through the inhibition of MutSβ with a compound as defined herein. The compounds as defined herein may be administered either as single agents or in combination with one or more additional agents.

[0239] The compounds as defined herein may be administered either as single agents or in combination with one or more disease modification therapies for Huntington’s Disease. Suitable disease modification therapies for Huntington’s disease include, but are not limited to RNA interference approaches (such as tominersen, WVE-003, AMT-130, BV-101, VO-659, SPK-miHTT, ALN-HTT02), mis-splicing (PTC-518) and antibody therapeutics (INT-41, NI-302, C6-17, VTx-003, ATLX-1095).

[0240] The compounds as defined herein may be administered either as single agents or in combination with one or more Huntingtin lowering therapies. Huntingtin lowering therapies may include approaches such as RNAi, miRNA (such as AMT-130), antisense oligonucleotides (such as tominersen), and small-molecule splicing modulators (such as PTC-518); and novel methods to clear the mHTT protein, such as proteolysis-targeting chimeras.

[0241] The present invention also provides methods for the treatment of repeat expansion diseases or disorders through the inhibition of MutSβ with a compound as defined herein. The compounds as defined herein may be administered either as single agents or in combination with one or more Huntingtin lowering therapies.

[0242] Thus, there is provided a combination comprising a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, and one or more Huntingtin lowering therapies.

[0243] According to a further aspect of the present invention, there is provided a method of treating a repeat expansion disease or disorder in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, and one or more Huntingtin lowering therapies.

[0244] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of a repeat expansion disease or disorder, wherein the compound or pharmaceutical composition is administered in combination with one or more Huntingtin lowering therapies.

[0245] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of a repeat expansion disease or disorder, wherein the compound or pharmaceutical composition is administered in combination with one or more Huntingtin lowering therapies.

[0246] The repeat expansion disease or disorder may be selected from any of those described herein, e.g. a triplet repeat disease or disorder.

[0247] Suitably, the triplet repeat disease or disorder is Huntington’s disease (HD).

[0248] Thus, there is provided a combination comprising a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, and one or more disease modification therapies for Huntington’s Disease. Suitable disease modification therapies for Huntington’s disease include, but are not limited to RNA interference approaches (such as tominersen, WVE-003, AMT-130, BV-101, VO-659, SPK-miHTT, ALN-HTT02), mis-splicing (PTC-518) and antibody therapeutics (INT-41, NI-302, C6-17, VTx-003, ATLX-1095).

[0249] According to a further aspect of the present invention, there is provided a method of treating Huntington’s disease in a patient, said method comprising administering to said patient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, and one or more disease modification therapies for Huntington’s disease.

[0250] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more disease modification therapies for Huntington’s disease.

[0251] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more disease modification therapies for Huntington’s disease.

[0252] The compounds as defined herein may be administered either as single agents or in combination with one or more Huntingtin lowering therapies, particularly in the treatment of Huntington’s disease. Huntingtin lowering therapies may include approaches such as RNAi, miRNA (such as AMT-130), antisense oligonucleotides (such as tominersen), and smallmolecule splicing modulators (such as PTC-518); and methods to clear the mHTT protein, such as proteolysis-targeting chimeras.

[0253] According to a further aspect of the present invention, there is provided a method of treating Huntington’s disease in a patient, said method comprising administering to saidpatient a therapeutically effective amount of a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, and one or more Huntingtin lowering therapies.

[0254] According to a further aspect of the present invention, there is provided a compound or a pharmaceutically acceptable salt, hydrate or solvate thereof as defined herein, or a pharmaceutical composition as defined herein, for use in the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more Huntingtin lowering therapies.

[0255] According to a further aspect of the present invention, there is provided the use of a compound, ora pharmaceutically acceptable salt, hydrate or solvate thereof, as defined herein in the manufacture of a medicament for the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more Huntingtin lowering therapies.

[0256] Herein, where the term “combination” is used it is to be understood that this refers to simultaneous, separate or sequential administration. In one aspect of the invention “combination” refers to simultaneous administration. In another aspect of the invention “combination” refers to separate administration. In a further aspect of the invention “combination” refers to sequential administration. Where the administration is sequential or separate, the delay in administering the second component should not be such as to lose the beneficial effect of the combination.

[0257] According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with an anti-tumour agent (optionally selected from one listed herein above), in association with a pharmaceutically acceptable diluent or carrier.NUMBERED PARAGRAPHSThe following numbered paragraphs are not claims but serve to define particular aspects of and embodiments of the invention.Paragraph 1. A compound, or a pharmaceutically acceptable salt thereof, having the structural formula (I) below:(I)wherein:Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2, 3 or 4;each occurrence of RL1and RL2is independently selected from hydrogen or (1-2C)alkyl), or RL1and RL2taken together may form an oxo group;XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXB1)C(O)-, -N(RXB1)-, -N(RXB1)C(O)O-, -OC(O)N(RXB1)-, -N(RXB1)C(O)N(RXB2)-, -S(O)2N(RXB1)-, or - N(RXB1)SO2-, wherein RXB1and RXB2are each independently selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQ1RQ2]n-, -[CRQ1RQ2]n-(3-10C)cycloalkyl, -[CRQ1RQ2]n-(3 to 10-membered heterocyclyl), - [CRQiRQ2]n-aryl and -[CRQ1RQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQ1and RQ2are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, NRQ3RQ4, C(O)RQ3,C(O)ORQ3, OC(O)RQ3, C(O)N(RQ3)RQ4, N(RQ3)C(O)RQ4, S(O)yRQ3(where y is 0, 1 or 2), SO2N(RQ3)RQ4or N(RQ3)SO2RQ4; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl;R2is selected from hydrogen and (1 -3C)alkyl;Rs is selected from hydrogen and (1 -3C)alkyl;bond a is either a single bond or a double bond, wherein:when bond a is a single bond:X is selected from -C(RXI)(RX2)-, -C(=O)-, -C(=NH)-, -C(=S)-; and Y is selected from -C(RYI)(RY2)-, -C(=O)-, -C(=NH)-, -C(=S)-; or when bond a is a double bond:X is -C(RX1)- andY is -C(RY1)-;wherein:RX1and RX2are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy;or RX1and RX2are linked such that, together with the carbon atom to which they are attached, form a (3-6C)cycloalkyl ring; RY1and RY2are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy;or RY1and RY2are linked such that, together with the carbon atom to which they are attached, form a (3-6C)cycloalkyl ring, optionally substituted with halo, hydroxy, (1-3C)alkyl or (1- 3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1- 3C)alkoxy;R4is selected from hydrogen, halo, cyano, hydroxy, NR4aR4b, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, -[CH2]r-(3-12C)cycloalkyl, -[CH2]r(3- to12-membered)heterocyclyl, -[CH2]raryl or -[CH2]r-heteroaryl wherein each of R4aand R4bis independently selected from hydrogen or (1 -3C)alkyl and integer r is 0, 1 or 2;wherein:any alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl in an R4group is optionally substituted by one or more Rie substituents independently selected from halo, hydroxy, cyano, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NR4aR4b, wherein R4aand R4b are each independently selected from H or (1- 2C)alkyl;Z is selected from -C(RZ2)(RZ3)-, -O-, or -NRzi, wherein:RZ1is selected from hydrogen or (1-2C)alkyl;RZ2and RZ3are each independently selected from hydrogen or (1 -3C)alkyl; or RZ2and RZ3are linked such that, together with the carbon atom to which they are attached, form a (3-5C)cycloalkyl or heterocyclyl ring;R5is selected from phenyl, naphthyl or heteroaryl, wherein R5is optionally substituted by one or more substituents RA, wherein each RA is independently selected from: halo, hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, cycloalkyl, (3-6-membered)heterocyclyl and -[CH2]s-NR5aR5b; wherein R5aand R5bare each independently selected from hydrogen or (1-2C)alkyl and integer s is 0, 1 or 2.Paragraph 2. A compound according to paragraph 1, or a pharmaceutically acceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2 or 3;each occurrence of RL1and RL2is independently selected from hydrogen or (1-2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXB1)C(O)- or -N(RXBI)-, wherein RXB1is selected from hydrogen and (1-2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQiRQ2]n-, -[CRQ1RQ2]n-(3-10C)cycloalkyl, -[CRQiRQ2]n-(3 to 10-membered heterocyclyl), - [CRaiRQ2]n-aryl or -[CRaiRQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQI and RQ2 are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, N(RQS)RQ4, C(O)RQS, C(O)ORQ3, OC(O)RQ3, C(O)N(RQ3)RQ4 or N(RQS)C(O)RQ4; wherein RQS and RQ4 are each independently selected from H or (1 -2C)alkyl.Paragraph 3. A compound according to paragraph 1 or paragraph 2, or a pharmaceutically acceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)- or-N(Rxsi)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQ1RQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQ1RQ2]n-(3 to 6-membered heterocyclyl), - [CRQiRQ2]n-phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; anddRQI and RQ2 are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl;optionally wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RLI and RL2 is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXB1)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQ1RQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQiRQ2]n-(3 to 6-membered heterocyclyl), - [CRQiRQ2]n-phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; andRQ1and RQ2are each independently selected from hydrogen or (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from hydrogen or methyl.Paragraph 4. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRi_iRL2]-, wherein:each occurrence of RL1and RL2is independently selected from hydrogen or methyl;XBis absent or is selected from the group consisting of -O-, -C(O)N(RXBI)-, wherein RXBI is selected from hydrogen and methyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQiRQ2]n- (3-6C)cycloalkyl, -[CRQiRQ2]n-(4 to 6-membered heterocyclyl), -[CRQiRQ2]n- phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0 or 1; andRQ1and RQ2are each independently selected from hydrogen and methyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4are each independently selected from H or (1 -2C)alkyl;optionally wherein Ri is a group of the formula:-LB-XB-QBwherein:LBis absent or -[CRL1RL2]-, wherein each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXBI)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, 3 to 6-membered heterocyclyl (e.g. oxetane, azetidine, 1,3- dioxolane or morpholine), phenyl or 5 or 6-membered heteroaryl; wherein:any QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy.Paragraph 5. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein Ri is a group with a formula selected from:Paragraph 6. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R2is selected from hydrogen or methyl; optionally wherein R2is hydrogen.Paragraph 7. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R3is selected from hydrogen or methyl; optionally wherein R3is hydrogen.Paragraph 8. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein bond a is either a single bond or a double bond, and wherein:when bond a is a single bond:X is -CH2-, andY is selected from -C(RYI)(RY2)- or-C(=0)-; orwhen bond a is a double bond:X is -CH- andY is -C(RY1)-;wherein:RYI and RY2 are each independently selected from hydrogen or (1- 2C)alkyl; oror RYI and RY2 are linked such that, together with the carbon atom to which they are attached, form a (3-4C)cycloalkyl ring.Paragraph 9. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein bond a is a single bond and:X is -CH2-, andY is -C(RYI)(RY2)-;wherein:RYI and RY2 are each independently selected from hydrogen or methyl; orRYI and RY2 are linked such that, together with the carbon atom to which they are attached, form a cyclopropyl ring.Paragraph 10. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-4C)alkyl (e.g. CH3or CD3), (1-4C)alkoxy, (1-4C)haloalkyl, (1- 4C)haloalkoxy, -[CH2]r-(3-6C)cycloalkyl, -[CH2]r-(3- to 7-membered)heterocyclyl, -[CH2]r- phenyl or -[CH2]r-(5- or 6-membered heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or (1 -2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or aminooptioally wherein R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-3C)alkyl (e.g. CH3orCD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3-6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or 6-membered heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or (1 -2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.Paragraph 11. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-3C)alkyl (e.g. CH3or CD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3- 6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or 6-membered heteroaryl; wherein:each of R4aand R4bis independently selected from hydrogen or methyl;any alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.Paragraph 12. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R4is selected from hydrogen, F or Cl, NR4aR4b, (1-2C)alkyl (e.g. CH3 or CDs), methoxy, (1-2C)haloalkyl, (3-4C)cycloalkyl, (4- to 5-membered)heterocyclyl or (5- or 6-membered heteroaryl;wherein:each of R4aand R4b is independently selected from hydrogen or methyl;any alkyl, cycloalkyl, heterocyclyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino;optionally wherein R4is methyl.Paragraph 13. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein Z is selected from -C(RZ2)(RZ3)-, -O-, - or -NRZ1; wherein:Rzi is selected from hydrogen or methyl; andRzz and Rzs are independently selected from hydrogen or methyl; optionally wherein Z is selected from -CH2-, -O- or -NRzi; wherein:Rzi is selected from hydrogen or methyl;further optionally wherein Z is -O-.Paragraph 14. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R5is selected from phenyl, 5- or 6- membered heteroaryl, or a bicyclic heteroaryl (e.g. a bicyclic heteroaryl comprising a phenyl ring fused to a 4- to 6 membered heterocyclic ring);wherein R5is optionally substituted by one or more substituents R, wherein each RAis independently selected from: halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, (3-6C)cycloalkyl, (3-6-membered)heterocyclyl and NRsaRsb; wherein R5aand R5b are each independently selected from hydrogen or methyl;optionally wherein R5is selected from phenyl, pyridyl, or a phenyl ring fused to a 4- to 6 membered heterocyclic ring;wherein R5is optionally substituted by one or more substituents RA, wherein each RAis independently selected from: halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6-membered)heterocyclyl;Paragraph 15. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:( RA^wherein a is an integer selected from 0, 1, 2, 3 or 4;each occurrence of RAis independently as defined in any one of the preceding paragraphs;optionally wherein each occurrence of RAis independently selected from: halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6-membered)heterocyclyl;optionally wherein each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, or methoxy;further optionally wherein each occurrence of RAis independently selected from fluoro or chloro.Paragraph 16. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:wherein a is an integer selected from 0, 1, 2 or 3;each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, methyl, methoxy, fluoromethyl, fluoromethoxy, (3-6C)cycloalkyl or (3-6- membered)heterocyclyl;optionally wherein each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, or methoxy;further optionally wherein each occurrence of RAis independently selected from fluoro or chloro.Paragraph 17. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:wherein:a is an integer selected from 0, 1, 2;each occurrence of RAis independently as defined in any one of the preceding paragraphs; andat least one occurrence of RAis in the meta position.Paragraph 18. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein R5is a group with a formula selected from:each of RAO and RAP are independently selected from hydrogen, fluoro and chloro; RAMI is selected from fluoro and chloro; andRAM2 is selected from fluoro and chloro;optionally wherein R5is a group a formula:each of RAOand RAPare independently selected from hydrogen, fluoro and chloro; RAMis selected from fluoro and chloro;wherein at least one of RAO and RAP is hydrogen, and the other is selected from fluoro and chloro.Paragraph 19. A compound according to any one of the preceding paragraphs, or a pharmaceutically acceptable salt thereof, wherein the compound has a structural formula (II) or (III) shown below:wherein R1, R2, R3, R4, R5, X, Y, Z and bond a are as defined in any one of the preceding paragraphs.Paragraph 20. A compound or a pharmaceutically acceptable salt thereof, selected from any one of the following:trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (fluoromethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;(R)-(6-(3-chlorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(oxetan-3-yl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3, 2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(isoxazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-cyclopropyl-2, 3-dihydro-1 H-pyrrolo[3, 2-b]pyridin-1 -yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(isoxazol-4-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(hydroxymethyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-ethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methyl-d3)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans- (6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -y I) (3-(2- (oxetan-3-yloxy)propan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2,2,2-trifluoroethyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-2-(3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-2-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;2-((2S,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;2-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;((2R,3R)-3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-2-(3-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan- 3-ylmethyl)oxiran-2-yl) methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-4-yl)oxiran-2-yl)methanone;trans-(3-(tert-butyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;Trans-(6-(3-fluoro-4-morpholinophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(3-(2-(benzyloxy)propan-2-yl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-cyclopropyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-4-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-phenyloxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isoxazol-5-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(oxetan-3-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-3-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-cyclopropyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-isopropyloxiran-2-yl)methanone;trans-(3-cyclopropyloxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)azetidine-3-carbonitrile;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl- 2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(fluoromethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(fluoromethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)-3-methylazetidine-3-carbonitrile;trans-(6-(2,6-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;trans-(3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;3-((5-methyl-1-((2R,3S)-3-methyloxirane-2-carbonyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(benzo[d][1,3]dioxol-5-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluoro-3-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-fluoro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;trans-3-((1-(3-(difluoromethyl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2S,3S)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-(6-((3,4-difluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)(methyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin- 1-yl)(3-methyloxiran-2-yl)methanone;(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methoxy-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorophenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6'-(3-chloro-4-fluorobenzyl)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-2,2,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone; or(6'-(4-fluorophenoxy)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)((2R,3S)-3-methyloxiran-2-yl)methanone.Paragraph 21. A compound or a pharmaceutically acceptable salt thereof, selected from any one of the following:trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (fluoromethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;(R)-(6-(3-chlorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(oxetan-3-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2- b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-cyclopropyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(isoxazol-4-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(hydroxymethyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-ethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methyl-d3)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-(oxetan-3-yloxy)propan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2,2,2-trifluoroethyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-2-(3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-2-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;2-((2S,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;2-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;((2R,3R)-3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-2-(3-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl) methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-4-yl)oxiran-2-yl)methanone;trans-(3-(tert-butyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-4-morpholinophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(3-(2-(benzyloxy)propan-2-yl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-cyclopropyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-4-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-phenyloxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-3-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-cyclopropyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-isopropyloxiran-2-yl)methanone;trans-(3-cyclopropyloxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isopropoxymethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)azetidine-3-carbonitrile;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(fluoromethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(fluoromethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)-3-methylazetidine-3-carbonitrile;trans-(6-(2,6-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;trans-(3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;3-((5-methyl-1-((2R,3S)-3-methyloxirane-2-carbonyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(benzo[d][1,3]dioxol-5-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluoro-3-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-fluoro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;trans-3-((1-(3-(difluoromethyl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-(6-((3,4-difluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)(methyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methoxy-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorophenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-3, 3, 5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6'-(3-chloro-4-fluorobenzyl)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-2,2,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6'-(4-fluorophenoxy)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;Cis-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl isobutyrate;trans-N-((3-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)acetamide;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxycyclobutyl)oxiran-2-yl)methanone;(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(3-hydroxyoxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(4-hydroxytetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((S)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(hydroxymethyl)oxiran-2-yl)methanone;(R)-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-3-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-bromophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-7-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(2,3,4-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(2R,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;trans-(6-(3-(difluoromethyl)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-(fluoromethyl)phenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-bromophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-5-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3-(trifluoromethoxy)phenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3,4,5-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-cyclopropyl-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-dichlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-(difluoromethoxy)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-5-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-5-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(6-(benzo[d][1,3]dioxol-4-yloxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2S,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-fluoro-2-methylpropyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (morpholine-4-carbonyl)oxiran-2-yl)methanone;trans-(3-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(quinolin-7-yloxy)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2R,3S)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-3-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- ((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-2-fluoro-6-((5-methyl-1-(3-(morpholinomethyl)oxirane-2-carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-3-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- (pyrimidin-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrimidin-5-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((2-fluoropyridin-4-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-azetidin-1-yl(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (3-methylpyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyrimidin-5-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyrimidin-2-yl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((5-fluoropyridin-3-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3- (pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(5-methyl-6-(pyridin-3-yloxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)- 5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone; ortrans-(6-((3-chlorophenyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone.Paragraph 22. A pharmaceutical composition comprising a compound according to any one of paragraphs 1 to 21, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.Paragraph 23. A compound according to any one of paragraphs 1 to 21 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to paragraph 22:a. for use in therapy;b. for use in the inhibition of MutSβ activity, e.g. in cellular systems;c. for use in the treatment of a disease or disorder in which MutSβ activity is implicated; d. for use in the treatment of a repeat expansion disease or disorder; optionally wherein the repeat expansion disease or disorder is selected from benign adult familial myoclo...

Claims

CLAIMS1. A compound, or a pharmaceutically acceptable salt thereof, having the structural formula (I) below:wherein:Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2, 3 or 4;each occurrence of RLI and RL2 is independently selected from hydrogen or (1 -2C)alkyl), or RLI and RL2 taken together may form an oxo group;XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXBI)C(O)-, -N(RXB1)-, -N(RXB1)C(O)O-, -OC(O)N(RXB1)-, -N(RXBI)C(O)N(RXB2)-, -S(O)2N(RXBI)-, or - N(RXBI)SO2-, wherein RXB1and RXB2are each independently selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQ1RQ2]n-, -[CRQiRQ2]n-(3-10C)cycloalkyl, -[CRQiRQ2]n-(3 to 10-membered heterocyclyl), - [CRQiRQ2]n-aryl and -[CRQiRQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQI and RQ2 are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, NRQSRCM, C(O)RQS, C(O)ORQ3, OC(O)RQ3, C(O)N(RQ3)RQ4, N(RQ3)C(O)RQ4, S(O)yRQ3(where y is 0, 1 or 2), SO2N(RQS)RQ4 or N(RQS)SO2RQ4; wherein RQS and RQ4are each independently selected from H or (1 -2C)alkyl;R2 is selected from hydrogen and (1 -3C)alkyl;R3is selected from hydrogen and (1 -3C)alkyl;bond a is either a single bond or a double bond, wherein:when bond a is a single bond:X is selected from -C(RXI)(RX2)-, -C(=O)-, -C(=NH)-, -C(=S)-; and Y is selected from -C(RYI)(RY2)-, -C(=O)-, -C(=NH)-, -C(=S)-; or when bond a is a double bond:X is -C(RX1)- andY is -C(RYI)-;wherein:RX1and RX2are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy; oror RX1and RX2are linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring;RYI and RY2 are each independently selected from hydrogen, halo, hydroxy, (1-3C)alkyl or (1-3C)alkoxy; and any alkyl is optionally further substituted with one or more substituents selected from: halo, hydroxy or (1-3C)alkoxy; oror RY1and RY2are linked such that, together with the carbon atom to which they are attached, they form a (3-6C)cycloalkyl ring, optionally substituted with halo, hydroxy, (1 -3C)alkyl or (1- 3C)alkoxy; and any alkyl is optionally further substituted withone or more substituents selected from: halo, hydroxy or (1- 3C)alkoxy;R4is selected from hydrogen, halo, cyano, hydroxy, NR4aR4b, (1-6C)alkyl, (1- 6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, -[CH2]r-(3-12C)cycloalkyl, -[CH2]r(3- to 12-membered)heterocyclyl, -[CH2]raryl or -[CH2]r-heteroaryl wherein each of R4aand R4bis independently selected from hydrogen or (1 -3C)alkyl and integer r is 0, 1 or 2;wherein:any alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl in an R4group is optionally substituted by one or more RI6substituents independently selected from halo, hydroxy, cyano, (1-3C)alkyl, (1-3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NR4aR4b, wherein R4aand R4bare each independently selected from H or (1- 2C)alkyl;Z is selected from -C(Rz2)(Rzs)-, -O-, or -NRzi, wherein:RZ1is selected from hydrogen or (1-2C)alkyl;RZ2and RZ3are each independently selected from hydrogen or (1 -3C)alkyl; or Rzz and Rzs are linked such that, together with the carbon atom to which they are attached, they form a (3-5C)cycloalkyl or heterocyclyl ring;R5is selected from phenyl, naphthyl or heteroaryl, wherein R5is optionally substituted by one or more substituents RA, wherein each RA is independently selected from: halo, hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)haloalkyl, (1-6C)haloalkoxy, cycloalkyl, (3-6-membered)heterocyclyl and -[CH2]s-NR5aR5b; wherein R5aand R5bare each independently selected from hydrogen or (1-2C)alkyl and integer s is 0, 1 or 2.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1, 2 or 3;each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -S(O)-, - S(O)2-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)N(RXB1)-, -N(RXB1)C(O)- or -N(RXB1)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQiRQ2]n-, -[CRQiRQ2]n-(3-10C)cycloalkyl, -[CRQiRQ2]n-(3 to 10-membered heterocyclyl), - [CRQiRQ2]n-aryl or -[CRQiRQ2]n-(5 to 10-membered heteroaryl); wherein:integer n is 0, 1 or 2; andRQI and RQ2 are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy, N(RQS)RQ4, C(O)RQS, C(O)ORQ3, OC(O)RQ3, C(O)N(RQS)RQ4 or N(RQS)C(O)RQ4; wherein RQS and RQ4are each independently selected from H or (1 -2C)alkyl.

3. A compound according to claim 1 or claim 2, or a pharmaceutically acceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RL1and RL2is independently selected from hydrogen or (1-2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXB1)C(O)- or-N(Rxsi)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -6C)alkyl, -[CRQ1RQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQ1RQ2]n-(3 to 6-membered heterocyclyl), - [CRoiRQ2]n-phenyl or -[CRaiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; anddRQ1and RQ2are each independently selected from hydrogen and (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQSRCM; wherein RQS and RQ4are each independently selected from H or (1 -2C)alkyl;optionally wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or-[CRLiRL2]m-, wherein:m is an integer selected from 1 or 2;each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXB1)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQiRQ2]n-, -[CRQiRQ2]n-(3-6C)cycloalkyl, -[CRQ1RQ2]n-(3 to 6-membered heterocyclyl), - [CRQiRQ2]n-phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0, 1 or 2; andRQI and RQ2 are each independently selected from hydrogen or (1- 2C)alkyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4 are each independently selected from hydrogen or methyl.

4. A compound according to any one of the preceding claims, or a pharmaceuticallyacceptable salt thereof, wherein Ri is selected from hydrogen or a group:-LB-XB-QBwherein:LBis absent or -[CRL1RL2]-, wherein:each occurrence of RL1and RL2is independently selected from hydrogen or methyl;XBis absent or is selected from the group consisting of -O-, -C(O)N(RXB1)-, wherein RXBI is selected from hydrogen and methyl;QBis selected from a group consisting of hydrogen, (1 -4C)alkyl, -[CRQiRQ2]n- (3-6C)cycloalkyl, -[CRQiRQ2]n-(4 to 6-membered heterocyclyl), -[CRQiRQ2]n- phenyl or -[CRQiRQ2]n-(5 or 6-membered heteroaryl); wherein:integer n is selected from 0 or 1; andRQI and RQ2 are each independently selected from hydrogen and methyl; andany QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -3C)alkyl, (1- 3C)alkoxy, (1-3C)haloalkyl, (1-3C)haloalkoxy or NRQ3RQ4; wherein RQ3and RQ4 are each independently selected from H or (1 -2C)alkyl; optionally wherein Ri is a group of the formula:-LB-XB-QBwherein:LBis absent or -[CRL1RL2]-, wherein each occurrence of RL1and RL2is independently selected from hydrogen or (1 -2C)alkyl);XBis absent or is selected from the group consisting of -O-, -S-, -C(O)-, - C(O)N(RXBI)-, -N(RXBI)C(O)-, -N(RXB1)-, wherein RXBI is selected from hydrogen and (1 -2C)alkyl;QBis selected from a group consisting of hydrogen, (1-4C)alkyl, (3- 6C)cycloalkyl, 3 to 6-membered heterocyclyl (e.g. oxetane, azetidine, 1,3- dioxolane or morpholine), phenyl or 5 or 6-membered heteroaryl; wherein:any QBis optionally further substituted with one or more substituents independently selected from: halo, oxo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy.

5. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Ri is a group with a formula selected from:F NC F HO6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R2is selected from hydrogen or methyl; optionally wherein R2is hydrogen.

7. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R3is selected from hydrogen or methyl; optionally wherein R3is hydrogen.

8. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein bond a is either a single bond or a double bond, and wherein:when bond a is a single bond:X is -CH2-, andY is selected from -C(RYI)(RY2)- or-C(=0)-; orwhen bond a is a double bond:X is -CH- andY is -C(RYI)-;wherein:RYI and RY2 are each independently selected from hydrogen or (1- 2C)alkyl; oror RYI and RY2 are linked such that, together with the carbon atom to which they are attached, they form a (3-4C)cycloalkyl ring.

9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein bond a is a single bond and:X is -CH2-, andY is -C(RYI)(RY2)-;wherein:RYI and RY2 are each independently selected from hydrogen or methyl; orRYI and RY2 are linked such that, together with the carbon atom to which they are attached, they form a cyclopropyl ring.

10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R4 is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-4C)alkyl (e.g. CH3or CD3), (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, -[CH2]r-(3-6C)cycloalkyl, -[CH2]r-(3- to 7-membered)heterocyclyl, -[CH2]r-phenyl or -[CH2]r-(5- or 6-membered heteroaryl;wherein:each of R4aand R4bis independently selected from hydrogen or (1-2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino;optionally wherein R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1 -3C)alkyl (e.g. CH3orCD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3-6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or 6-membered heteroaryl;wherein:each of R4a and R4b is independently selected from hydrogen or (1 -2C)alkyl and integer r is 0 or 1; andany alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.

11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R4is selected from hydrogen, halo (e.g. F or Cl), NR4aR4b, (1-3C)alkyl (e.g. CH3or CD3), (1-2C)alkoxy, (1-3C)haloalkyl, (3-6C)cycloalkyl, (4- to 6-membered)heterocyclyl, phenyl or (5- or 6-membered heteroaryl;wherein:each of R4aand R4b is independently selected from hydrogen or methyl;any alkyl, cycloalkyl, heterocyclyl, phenyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino.

12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R4is selected from hydrogen, F or Cl, NR4aR4b, (1 -2C)alkyl (e.g. CH3or CD3), methoxy, (1-2C)haloalkyl, (3-4C)cycloalkyl, (4- to 5-membered)heterocyclyl or (5- or 6-membered heteroaryl;wherein:each of R4aand R4b is independently selected from hydrogen or methyl;any alkyl, cycloalkyl, heterocyclyl or heteroaryl in an R4group is optionally substituted by one or more substituents independently selected from halo, hydroxy, cyano or amino;optionally wherein R4is methyl.

13. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein Z is selected from -C(RZ2)(RZ3)-, -O-, - or -NRZ1; wherein:Rzi is selected from hydrogen or methyl; andRzz and RZ3are independently selected from hydrogen or methyl; optionally wherein Z is selected from -CH2-, -O- or -NRzi; wherein:Rzi is selected from hydrogen or methyl;further optionally wherein Z is -O-.

14. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5is selected from phenyl, 5- or 6-membered heteroaryl, or a bicyclic heteroaryl (e.g. a bicyclic heteroaryl comprising a phenyl ring fused to a 4- to 6 membered heterocyclic ring);wherein R5is optionally substituted by one or more substituents RA, wherein each RAis independently selected from: halo, hydroxy, cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)haloalkyl, (1-4C)haloalkoxy, (3-6C)cycloalkyl, (3-6- membered)heterocyclyl and NRsaRsb; wherein Rsa and Rsb are each independently selected from hydrogen or methyl;optionally wherein R5is selected from phenyl, pyridyl, or a phenyl ring fused to a 4- to 6 membered heterocyclic ring;wherein R5is optionally substituted by one or more substituents RA, wherein each RAis independently selected from: halo, hydroxy, cyano, (1 -2C)alkyl, (1- 2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6- membered)heterocyclyl.

15. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:wherein a is an integer selected from 0, 1, 2, 3 or 4;each occurrence of RAis independently as defined in any one of the preceding claims;optionally wherein each occurrence of RAis independently selected from: halo, hydroxy, cyano, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl, (1-2C)haloalkoxy, (3-6C)cycloalkyl or (3-6-membered)heterocyclyl;optionally wherein each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, or methoxy;further optionally wherein each occurrence of RAis independently selected from fluoro or chloro.

16. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:wherein a is an integer selected from 0, 1, 2 or 3;each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, methyl, methoxy, fluoromethyl, fluoromethoxy, (3-6C)cycloalkyl or (3-6- membered)heterocyclyl;optionally wherein each occurrence of RAis independently selected from fluoro, chloro, hydroxy, cyano, or methoxy;further optionally wherein each occurrence of RAis independently selected from fluoro or chloro.

17. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5is a group of the formula:wherein:a is an integer selected from 0, 1, 2;each occurrence of RAis independently as defined in any one of the preceding claims; andat least one occurrence of RA is in the meta position.

18. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R5is a group with a formula selected from:each of RAO and RAP are independently selected from hydrogen, fluoro and chloro; RAMI is selected from fluoro and chloro; andRAM2 is selected from fluoro and chloro;optionally wherein Rs is a group a formula:each of RAOand RAPare independently selected from hydrogen, fluoro and chloro; RAMis selected from fluoro and chloro;wherein at least one of RAO and RAP is hydrogen, and the other is selected from fluoro and chloro.

19. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein the compound has a structural formula (II) shown below:wherein R1, R2, R3, R4, R5, X, Y, Z and bond a are as defined in any one of the preceding claims.

20. A compound or a pharmaceutically acceptable salt thereof, selected from any one of the following:trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (fluoromethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)- 3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;(R)-(6-(3-chlorobenzyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2- yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(oxetan-3-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4- fluoro benzyl)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3, 2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(isoxazol-5-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-cyclopropyl-2, 3-dihydro-1 H-pyrrolo[3, 2-b]pyridin-1 -yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-ch loro-4- fluoro benzyl)-5-(isoxazol-4-yl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(hydroxymethyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-ethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-methoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-5-(methyl-d3)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorobenzyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-methoxypropan-2-yl)oxiran-2-yl)methanone;trans- (6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-(oxetan-3-yloxy)propan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methyloxetan-3-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2,2,2-trifluoroethyl)oxiran-2-yl)methanone;trans-(3-(2,2-difluoroethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-2-(3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-2-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-ylmethyl)oxiran-2-yl)methanone;2-((2S,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;2-((2S,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;((2R,3R)-3-(1,3-dioxolan-2-yl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-2-(3-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2-methylpropanenitrile;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan- 3-ylmethyl)oxiran-2-yl) methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-4-yl)oxiran-2-yl)methanone;trans-(3-(tert-butyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-4-morpholinophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(3-(2-(benzyloxy)propan-2-yl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-phenyloxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-cyclopropyloxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-4-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-phenyloxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-methyl-1 H-pyrazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (oxetan-3-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (isoxazol-5-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (oxetan-3-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-3-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-cyclopropyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-3-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isoxazol-5-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-isopropyloxiran-2-yl)methanone;trans-(3-cyclopropyloxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-fluoro-2-hydroxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluoro-2-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)azetidine-3-carbonitrile;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-methoxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((3,3-difluoroazetidin-1-yl)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-fluoroazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3-hydroxyazetidin-1-yl)methyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(isopropoxymethyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((2,2-dimethylazetidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- ((dimethylamino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (morpholinomethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-(azetidin-1-ylmethyl)oxiran-2-yl)(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(fluoromethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((dimethylamino)methyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(fluoromethyl)oxiran-2-yl)methanone;trans-1-((3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)-3-methylazetidine-3-carbonitrile;trans-(6-(2,6-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;trans-(3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;3-((5-methyl-1-((2R,3S)-3-methyloxirane-2-carbonyl)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(benzo[d][1,3]dioxol-5-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluoro-3-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-fluoro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;trans-3-((1-(3-(difluoromethyl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-(4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(difluoromethyl)oxiran-2-yl)(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1 -carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N,N-dimethyloxirane-2-carboxamide;trans-(6-((3,4-difluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(oxetan-3-ylmethyl)oxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)(methyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-((3-chloro-4-fluorophenyl)amino)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methoxy-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-fluoro-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(5-chloro-6-(3-chloro-4-fluorophenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorobenzyl)-3,3-dimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6'-(3-chloro-4-fluorobenzyl)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-fluorophenoxy)-2,2,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;(6'-(4-fluorophenoxy)-5'-methylspiro[cyclopropane-1,3'-pyrrolo[3,2-b]pyridin]-1'(2'H)-yl)((2R,3S)-3-methyloxiran-2-yl)methanone;Cis-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl isobutyrate;trans-N-((3-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methyl)acetamide;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-ethyloxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxycyclobutyl)oxiran-2-yl)methanone;(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(3-hydroxyoxetan-3-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(4-hydroxytetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(hydroxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((S)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((R)-1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(hydroxymethyl)oxiran-2-yl)methanone;(R)-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-ethyloxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(1-hydroxyethyl)oxiran-2-yl)methanone;trans-(6-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-3-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(methoxymethyl)oxiran-2-yl)methanone;(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-methylphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-bromophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-7-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(2,3,4-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(2R,3R)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide; trans-(6-(3-(difluoromethyl)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-(fluoromethyl)phenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-bromophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-2-fluoro-5-((1-(3-(2-hydroxypropan-2-yl)oxirane-2-carbonyl)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3-(trifluoromethoxy)phenoxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(3,4,5-trifluorophenoxy)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(3-cyclopropyl-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-5-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-dichlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-(difluoromethoxy)-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(4-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indazol-5-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-5-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-((1H-indol-6-yl)oxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-chloro-3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-hydroxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(2R,3R)-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(6-(benzo[d][1,3]dioxol-4-yloxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-2-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2-fluoro-3-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;((2R,3S)-3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-(1-fluoro-2-methylpropan-2-yl)-N-methyloxirane-2-carboxamide;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2S,3R)-3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-phenoxy-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-fluoro-2-methylpropyl)oxiran-2-yl)(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(morpholine-4-carbonyl)oxiran-2-yl)methanone;trans-(3-(2-oxa-6-azaspiro[3.3]heptane-6-carbonyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone;(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-3-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)-N-methyloxirane-2-carboxamide;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(6-(isoquinolin-7-yloxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(2-hydroxypropan-2-yl)oxiran-2-yl)(5-methyl-6-(quinolin-7-yloxy)-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-((3,3-difluoropyrrolidin-1-yl)methyl)oxiran-2-yl)methanone;3-((2R,3S)-3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-3-(3-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-2,2-dimethylpropanenitrile;(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-((3,3-difluoropiperidin-1-yl)methyl)oxiran-2-yl)methanone;(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(3-(((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(3-((3-oxa-6-azabicyclo[3.1.1]heptan-6-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methoxyphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-((R)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-((S)-tetrahydrofuran-2-yl)oxiran-2-yl)methanone;trans-(6-(4-fluoro-3-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-chlorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxy-2-methylpropyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-2-fluoro-6-((5-methyl-1-(3-(morpholinomethyl)oxirane-2-carbonyl)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-6-yl)oxy)benzonitrile;trans-3-(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)-1 -methylpyridin-2(1 H)-one;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-4-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2S,3R)-3- (pyrimidin-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-3,3,5-trimethyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(pyrimidin-5-yl)oxiran-2-yl)methanone;trans-(6-(3,5-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-((1-hydroxycyclopropyl)methyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((2-fluoropyridin-4-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((6-fluoropyridin-2-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;((2R,3S)-3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(3-fluoropyridin-2-yl)oxiran-2-yl)methanone;(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;trans-azetidin-1-yl(3-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridine-1-carbonyl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(3-methylpyridin-2-yl)oxiran-2-yl)methanone;(6-(3-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3R)-3-(2-fluoropropan-2-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-((3,3-dimethylmorpholino)methyl)oxiran-2-yl)methanone;((2R,3S)-3-((7-oxa-4-azaspiro[2.5]octan-4-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)methanone; trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(pyrazin-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(pyrimidin-5-yl)oxiran-2-yl)methanone;(6-(3,4-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3-(hydroxymethyl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyrimidin-2-yl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(6-((5-fluoropyridin-3-yl)oxy)-5-methyl-2,3-dihydro- 1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)( 3-(pyridazin-3-yl)oxiran-2-yl)methanone;trans-(6-(3-fluoro-2-methylphenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)( 3-(morpholinomethyl)oxiran-2-yl)methanone;trans-(3-(difluoromethyl)oxiran-2-yl)(5-methyl-6-(pyridin-3-yloxy)-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-(dimethylamino)-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(pyridin-2-yl)oxiran-2-yl)methanone;trans-(6-(3-chloro-4-fluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3-(2-hydroxypropan-2-yl)oxiran-2-yl)methanone;trans-(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)(3- (tetrahydro-2H-pyran-4-yl)oxiran-2-yl)methanone;(6-(2,3-difluorophenoxy)-5-methyl-2,3-dihydro-1H-pyrrolo[3,2-b]pyridin-1-yl)((2R,3S)-3- (pyridin-2-yl)oxiran-2-yl)methanone;trans-(3-((6-oxa-1-azaspiro[3.3]heptan-1-yl)methyl)oxiran-2-yl)(6-(2,3-difluorophenoxy)- 5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1 -yl)methanone; ortrans-(6-((3-chlorophenyl)amino)-5-methyl-2,3-dihydro-1 H-pyrrolo[3,2-b]pyridin-1-yl)(3- ethyloxiran-2-yl)methanone.

21. A pharmaceutical composition comprising a compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

22. A compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21 for use in therapy.

23. A compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21:a. for use in the inhibition of MutSβ activity, e.g. in cellular systems;b. for use in the treatment of a disease or disorder in which MutSβ activity is implicated; c. for use in the treatment of a repeat expansion disease or disorder; optionally wherein the repeat expansion disease or disorder is selected from benign adult familial myoclonic epilepsy (BAFME); brachydactyly and cleidocranial dysplasia (BCCD); blepharophimosis, ptosis and epicanthus inversus (BPES); Baratela-Scott syndrome (BSS); cerebellar ataxia, neuropathy and vestibular areflexia syndrome (CANVAS); congenital central hypoventilation syndrome (CCHS); dentatorubropallidoluysian atrophy (DRPLA); early infantile epileptic encephalopathy type 1 (EIEE1); familial adult myoclonic epilepsy (FAME); Fuch’s endothelial corneal dystrophy type 3 (FECD3); Dentatorubral pallidoluysian atrophy; fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA) frontotemporal dementia / amyotrophic lateral sclerosis (FTD / ALS); fragile X- associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X- associated tremor ataxia syndrome (FXTAS); global development delay, progressive ataxia and elevated glutamine (GDPAG); Huntington’ s disease (HD); Huntington disease-like 2 (HDL2); hand-foot-genital syndrome (HFGS); holoprosencephaly type 5 (HPE5); mental retardation with isolated growth hormone deficiency (MRGH);myotonic dystrophy type 1 (DM1); myotonic dystrophy type 2 (DM2); progressive myoclonus epilepsy type 1 or Unverricht-Lundborg diseae (EPM1); neuronal intranuclear inclusion disease (NIID); oculopharyngodistal myopathy type 1 (OPDM1); oculopharyngodistal myopathy type 2 (OPDM2); oculopharyngeal myopathy with leukoencephalopathy type 1 (OPML1); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 10, 12, 17, 27B, 31, 36 or 37 (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA12, SCA17, SCA27B, SCA31, SCA36, SCA37); syn polydactyly (SPD); X-linked dystonia parkinsonism (XDP); X- linked mental retardation and abnormal genitalia (XLAG); or X-linked mental retardation with or without growth hormone deficiency (XLMR, XLMRGHD);d. for use in the treatment of a triplet repeat disease or disorder, e.g.dentatorubropallidoluysian atrophy (DRPLA); Fuch’s endothelial corneal dystrophy type 3 (FECD3); fragile XE syndrome (FRAXE); Friedreich ataxia (FRDA); fragile X- associated premature ovarian infertility (FXPOI); fragile X syndrome (FXS); fragile X- associated tremor ataxia syndrome (FXTAS); Huntington’ s disease (HD); Huntington disease-like 2 (HDL2); myotonic dystrophy type 1 (DM1); neuronal intranuclear inclusion disease (NIID); spinobulbar muscular atrophy (SBMA); spinocerebellar ataxias type 1, 2, 3, 6, 7, 8, 17 or 27B (SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA17 or SCA27B);e. for use in the treatment of Huntington’s disease (HD);f. for use in inhibiting somatic expansion of expanded simple nucleotide repeats in a subject, e.g. in the treatment of a repeat expansion disease or disorder;g. for use in the inhibition of somatic expansion of expanded simple nucleotide repeats in a subject carrying a disease allele for a repeat expansion disease or disorder; h. for use in the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more disease modification therapies, e.g. RNA interference approaches (such as tominersen, WVE-03, AMT-130, BV-101, VO-659 or SPK-miHTT), mis-splicing (such as PTC- 518) and antibody therapeutics (such as INT-41, NI-302, C6-17 or Vtx-003);i. for use in the treatment of Huntington’s disease, wherein the compound or pharmaceutical composition is administered in combination with one or more Huntingtin lowering therapies (such as RNAi, miRNA (such as AMT-130), antisense oligonucleotides (such as tominersen), and small-molecule splicing modulators (such as PTC-518); and novel methods to clear the mHTT protein, such as proteolysis-targeting chimeras);j. for use in gene editing in vitro, ex vivo or in vivo; optionally wherein the gene editing method is selected from CRISPR-Cas9, CRISPR-Cas12, Fanzor, ZFN (zinc finger nucleases), TALENs, base editors and prime editors;k. for use as an agent to enhance the efficiency of prime editors;l. for use as an agent to reduce off-target editing (errors) of prime editors in cellular systems;m. for use as an agent to both enhance efficiency and reduce error of prime editors in cellular systems;n. for use as an agent to enhance the efficiency of prime editor therapeutics ex vivo (e.g.allogeneic editing of hematopoietic cells); oro. for use as an agent to enhance the efficiency of prime editor therapeutics in vivo.

24. The use of compound according to any one of claims 1 to 20 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 21:a. in inhibiting somatic expansion of expanded simple nucleotide repeats in a cellular assay system;b. as an agent to enhance the efficiency of prime editors in a cellular system; c. as an agent to reduce off-target editing (errors) of prime editors in cellular systems;d. as an agent to both enhance efficiency and reduce error of prime editors in cellular systems;e. as an agent to enhance the efficiency of prime editor therapeutics ex vivo (e.g.allogeneic editing of hematopoietic cells);f. as an agent to inhibit mismatch repair in vitro, ex vivo or in vivo; g. in testing an agent for the ability to inhibit ATP hydrolysis by MutSβ in the presence or absence of a suitable heteroduplex DNA substrate; or h. in testing an agent for the ability to inhibit ATP-dependent recruitment of MutLα or MutLβ or MutLγ by MutSβ.

25. A method of increasing the efficiency of a gene editing technique or reducing the error rate of a gene editing technique, the method comprising conducting the gene editing technique in the presence of a compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof; optionally wherein the gene editing technique is a gene editing technique in which host cell mis-match repair (MMR) factors are known to decrease the efficiency of the gene editing, e.g.:homology-directed repair (HDR),non-homologous end joining (NHEJ),ZFN (zinc finger nucleases),TALENs (Transcription activator like effector nucleases),CRISPR-Cas9 nucleases,CRISPR-Cas12 nucleases,base editing (fusion of catalytically dead dCas9 enzymes to DNA deaminases which enable single nucleotide substitutions),prime editing (fusion of a Cas9 nickase to a reverse transcriptase),PASTE (programmable addition via site-specific targeting elements which leverages prime editing to insert AttB sites and then facilitate serine integrase proteins to insert larger sequences), orany editing method using a single-stranded oligonucleotide (ssODN) as a template including nuclease-free editing methods.

26. A method of prime editing, the method comprising contacting a cell with: (1) a Cas9 nickase to nick a non-target strand; (2) a prime editing single guide RNA (pegRNA) to bind the target strand; (3) a reverse transcriptase to reverse transcribe from the 3’ end of the nontarget strand according to the information provided by the pegRNA; and (4) a compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof.

Images